Sheng-Yong Niu
commited on
Upload 7 files
Browse files
.gitattributes
CHANGED
@@ -33,3 +33,4 @@ saved_model/**/* filter=lfs diff=lfs merge=lfs -text
|
|
33 |
*.zip filter=lfs diff=lfs merge=lfs -text
|
34 |
*.zst filter=lfs diff=lfs merge=lfs -text
|
35 |
*tfevents* filter=lfs diff=lfs merge=lfs -text
|
|
|
|
33 |
*.zip filter=lfs diff=lfs merge=lfs -text
|
34 |
*.zst filter=lfs diff=lfs merge=lfs -text
|
35 |
*tfevents* filter=lfs diff=lfs merge=lfs -text
|
36 |
+
data/Dabrafenib.MIA_PaCa-2.h5ad filter=lfs diff=lfs merge=lfs -text
|
data/Dabrafenib.MIA_PaCa-2.h5ad
ADDED
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
1 |
+
version https://git-lfs.github.com/spec/v1
|
2 |
+
oid sha256:e4de17c5e96499a7428db44afcf1c6dd7a0f3fee1ea36facf52248335ce5c120
|
3 |
+
size 690008
|
data/chemberta_cls_embeddings.csv
ADDED
The diff for this file is too large to render.
See raw diff
|
|
data/drivergene_cellline_matrix.parquet
ADDED
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
1 |
+
version https://git-lfs.github.com/spec/v1
|
2 |
+
oid sha256:6aedd3177c3dfc1d1937ab37cbfc113b71a1e611c6ddb63b1c82afb1fd09437e
|
3 |
+
size 23463
|
data/drug_summaries.json
ADDED
@@ -0,0 +1,1897 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
+
{
|
2 |
+
"Decitabine": [
|
3 |
+
"DNA methyltransferase, DNMT1, DNMT3A, DNMT3B",
|
4 |
+
"Apoptosis, cell cycle regulation, DNA damage response, epigenetic regulation",
|
5 |
+
"Myelodysplastic syndromes, acute myeloid leukemia"
|
6 |
+
],
|
7 |
+
"Methotrexate": [
|
8 |
+
"Dihydrofolate reductase, folate receptor",
|
9 |
+
"Cell cycle regulation, DNA synthesis, apoptosis",
|
10 |
+
"Rheumatoid arthritis, psoriasis, leukemia, lymphoma"
|
11 |
+
],
|
12 |
+
"Delamanid": [
|
13 |
+
"Mycolic acid synthase I",
|
14 |
+
"Cell wall biosynthesis, oxidative phosphorylation, fatty acid biosynthesis",
|
15 |
+
"Multidrug-resistant tuberculosis"
|
16 |
+
],
|
17 |
+
"Demeclocycline": [
|
18 |
+
"30S ribosomal subunit",
|
19 |
+
"Protein synthesis, cell growth, and division",
|
20 |
+
"Siadh, neurogenic diabetes insipidus, inappropriate antidiuretic hormone secretion"
|
21 |
+
],
|
22 |
+
"5-Fluorouracil": [
|
23 |
+
"Thymidylate synthase, dihydrofolate reductase",
|
24 |
+
"DNA synthesis, cell cycle regulation, apoptosis",
|
25 |
+
"Colorectal cancer, breast cancer, stomach cancer, pancreatic cancer"
|
26 |
+
],
|
27 |
+
"LB-100": [
|
28 |
+
"Serine/threonine protein phosphatase 2A (PP2A)",
|
29 |
+
"Cell cycle regulation, apoptosis, and DNA damage response",
|
30 |
+
"Acute myeloid leukemia, solid tumors"
|
31 |
+
],
|
32 |
+
"Glycyrrhizic acid": [
|
33 |
+
"11\u03b2-Hydroxysteroid dehydrogenase, Toll-like receptors, NF-\u03baB",
|
34 |
+
"Inflammation, immune response, glucocorticoid metabolism",
|
35 |
+
"Peptic ulcer, hepatitis, gastritis"
|
36 |
+
],
|
37 |
+
"(S)-Crizotinib": [
|
38 |
+
"MET, ROS1, ALK",
|
39 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
40 |
+
"Non-small cell lung cancer, ROS1-positive non-small cell lung cancer, ALK-positive non-small cell lung cancer"
|
41 |
+
],
|
42 |
+
"Nafamostat (mesylate)": [
|
43 |
+
"Serine proteases, factor VIIa, factor Xa, thrombin, complement system, plasma kallikrein",
|
44 |
+
"Coagulation cascade, complement system, kinin-kallikrein system, fibrinolysis",
|
45 |
+
"Disseminated intravascular coagulation, acute pancreatitis, shock, extracorporeal circulation"
|
46 |
+
],
|
47 |
+
"Diammonium Glycyrrhizinate": [
|
48 |
+
"Toll-like receptors, glucocorticoid receptors, nuclear factor-kappa B",
|
49 |
+
"Inflammatory response, immune response, apoptosis",
|
50 |
+
"Viral hepatitis, liver fibrosis, gastric ulcers"
|
51 |
+
],
|
52 |
+
"Vinblastine (sulfate)": [
|
53 |
+
"Tubulin",
|
54 |
+
"Cell cycle arrest, apoptosis, angiogenesis inhibition",
|
55 |
+
"Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, breast cancer, choriocarcinoma"
|
56 |
+
],
|
57 |
+
"AZD-7648": [
|
58 |
+
"CDK1, CDK2, CDK4, CDK6",
|
59 |
+
"Cell cycle progression, DNA replication, G1/S transition",
|
60 |
+
"Breast cancer, non-small cell lung cancer, ovarian cancer"
|
61 |
+
],
|
62 |
+
"Dinaciclib": [
|
63 |
+
"CDK1, CDK2, CDK5, CDK9",
|
64 |
+
"Cell cycle regulation, Apoptosis, DNA replication",
|
65 |
+
"None"
|
66 |
+
],
|
67 |
+
"Erlotinib": [
|
68 |
+
"Epidermal Growth Factor Receptor (EGFR)",
|
69 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
70 |
+
"Non-small cell lung cancer, Pancreatic cancer"
|
71 |
+
],
|
72 |
+
"Almonertinib (hydrochloride)": [
|
73 |
+
"MET, AXL, DDR2",
|
74 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
75 |
+
"Non-small cell lung cancer"
|
76 |
+
],
|
77 |
+
"Daptomycin": [
|
78 |
+
"Bacterial cell membrane",
|
79 |
+
"Bacterial cell division, membrane potential, cell wall synthesis",
|
80 |
+
"Complicated skin and skin structure infections, bacteremia, right-sided infective endocarditis, Staphylococcus aureus bloodstream infections"
|
81 |
+
],
|
82 |
+
"Sulfatinib": [
|
83 |
+
"VEGFR, FGFR, CSF1R",
|
84 |
+
"Angiogenesis, tumor growth, immune response",
|
85 |
+
"Thyroid cancer, pancreatic neuroendocrine tumors"
|
86 |
+
],
|
87 |
+
"Tolmetin": [
|
88 |
+
"COX-1, COX-2",
|
89 |
+
"Prostaglandin synthesis, Inflammatory response, Pain perception",
|
90 |
+
"Osteoarthritis, Rheumatoid arthritis, Juvenile rheumatoid arthritis"
|
91 |
+
],
|
92 |
+
"Idarubicin (hydrochloride)": [
|
93 |
+
"DNA topoisomerase II, DNA",
|
94 |
+
"Apoptosis, cell cycle arrest, DNA damage response",
|
95 |
+
"Acute myeloid leukemia, breast cancer, lymphomas"
|
96 |
+
],
|
97 |
+
"Dexamethasone": [
|
98 |
+
"Glucocorticoid receptor",
|
99 |
+
"Inflammation, immune response, apoptosis, cell growth",
|
100 |
+
"Cerebral edema, inflammatory conditions, immune system disorders, cancer, respiratory distress syndrome"
|
101 |
+
],
|
102 |
+
"Loperamide (hydrochloride)": [
|
103 |
+
"Mu-opioid receptors",
|
104 |
+
"Intestinal motility pathways, gut secretion pathways, opioid receptor signaling pathways",
|
105 |
+
"Diarrhea, acute diarrhea, chronic diarrhea, traveler's diarrhea, diarrhea associated with inflammatory bowel disease"
|
106 |
+
],
|
107 |
+
"Fostamatinib (disodium hexahydrate)": [
|
108 |
+
"Syk (spleen tyrosine kinase)",
|
109 |
+
"B-cell receptor signaling, immune cell activation, and inflammation",
|
110 |
+
"Chronic immune thrombocytopenia in adults who have had an insufficient response to a previous treatment"
|
111 |
+
],
|
112 |
+
"APTO-253": [
|
113 |
+
"c-Myc",
|
114 |
+
"Cell cycle regulation, apoptosis, transcriptional regulation",
|
115 |
+
"Acute myeloid leukemia, myelodysplastic syndrome"
|
116 |
+
],
|
117 |
+
"Quinidine (15% dihydroquinidine)": [
|
118 |
+
"Sodium channels, potassium channels, hERG channels",
|
119 |
+
"Cardiac action potential, atrioventricular node conduction, ventricular repolarization",
|
120 |
+
"Atrial fibrillation, atrial flutter, ventricular tachycardia, paroxysmal supraventricular tachycardia"
|
121 |
+
],
|
122 |
+
"Lapatinib ditosylate": [
|
123 |
+
"Epidermal Growth Factor Receptor, Human Epidermal Growth Factor Receptor 2",
|
124 |
+
"PI3K/AKT, MAPK/ERK, cell cycle regulation",
|
125 |
+
"Breast cancer"
|
126 |
+
],
|
127 |
+
"Pioglitazone": [
|
128 |
+
"Peroxisome proliferator-activated receptor gamma (PPAR\u03b3)",
|
129 |
+
"Insulin signaling pathway, glucose metabolism, lipid metabolism",
|
130 |
+
"Type 2 diabetes mellitus"
|
131 |
+
],
|
132 |
+
"Nimesulide": [
|
133 |
+
"COX-2, COX-1",
|
134 |
+
"Inflammation, pain, prostaglandin synthesis, cell adhesion",
|
135 |
+
"Pain, inflammation, fever, osteoarthritis, rheumatoid arthritis"
|
136 |
+
],
|
137 |
+
"Paclitaxel": [
|
138 |
+
"Beta-tubulin",
|
139 |
+
"Cell cycle arrest, apoptosis, angiogenesis inhibition",
|
140 |
+
"Breast cancer, ovarian cancer, non-small cell lung cancer, AIDS-related Kaposi's sarcoma, pancreatic cancer"
|
141 |
+
],
|
142 |
+
"Lenalidomide (hemihydrate)": [
|
143 |
+
"CRBN, IKZF1, IKZF3, CK1\u03b1",
|
144 |
+
"NF-\u03baB, cell cycle regulation, apoptosis, immune response",
|
145 |
+
"Multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma"
|
146 |
+
],
|
147 |
+
"AT7519": [
|
148 |
+
"CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9",
|
149 |
+
"Cell cycle progression, DNA replication, transcription, apoptosis",
|
150 |
+
"None"
|
151 |
+
],
|
152 |
+
"Drospirenone": [
|
153 |
+
"Progesterone receptor, mineralocorticoid receptor, androgen receptor",
|
154 |
+
"Hypothalamic-pituitary-ovarian axis, renin-angiotensin-aldosterone system, estrogen-related pathways",
|
155 |
+
"Premenstrual dysphoric disorder, contraception, premenstrual syndrome, polycystic ovary syndrome, acne, hirsutism"
|
156 |
+
],
|
157 |
+
"Gefitinib": [
|
158 |
+
"Epidermal Growth Factor Receptor (EGFR)",
|
159 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
160 |
+
"Non-small cell lung cancer"
|
161 |
+
],
|
162 |
+
"ETC-206": [
|
163 |
+
"GPR40, S1P1",
|
164 |
+
"Insulin secretion, Glucose metabolism, Lipid metabolism",
|
165 |
+
"Type 2 diabetes mellitus"
|
166 |
+
],
|
167 |
+
"Binimetinib": [
|
168 |
+
"MEK1, MEK2",
|
169 |
+
"MAPK/ERK signaling, PI3K/AKT signaling, cell cycle regulation",
|
170 |
+
"Adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with encorafenib"
|
171 |
+
],
|
172 |
+
"Relugolix": [
|
173 |
+
"Gonadotropin-releasing hormone receptor",
|
174 |
+
"Hypothalamic-pituitary-gonadal axis, follicle-stimulating hormone regulation, luteinizing hormone regulation",
|
175 |
+
"Uterine fibroids, endometriosis, prostate cancer"
|
176 |
+
],
|
177 |
+
"Resveratrol": [
|
178 |
+
"SIRT1, AMPK, NF-\u03baB, PI3K/Akt",
|
179 |
+
"Inflammation, apoptosis, cell cycle regulation, insulin signaling",
|
180 |
+
"None"
|
181 |
+
],
|
182 |
+
"MK-8353": [
|
183 |
+
"ERK1/2, MEK1/2",
|
184 |
+
"MAPK signaling, cell proliferation, apoptosis",
|
185 |
+
"Melanoma, non-small cell lung cancer, thyroid cancer"
|
186 |
+
],
|
187 |
+
"Belumosudil (mesylate)": [
|
188 |
+
"ROCK1, ROCK2",
|
189 |
+
"PI3K/AKT, MAPK/ERK, NF-\u03baB",
|
190 |
+
"Chronic graft-versus-host disease"
|
191 |
+
],
|
192 |
+
"Canagliflozin (hemihydrate)": [
|
193 |
+
"Sodium-glucose cotransporter 2 (SGLT2)",
|
194 |
+
"Glucose reabsorption, insulin secretion, glucagon secretion, ketone production",
|
195 |
+
"Type 2 diabetes mellitus, heart failure, chronic kidney disease"
|
196 |
+
],
|
197 |
+
"Radotinib": [
|
198 |
+
"BCR-ABL, c-KIT, PDGFR, SRC",
|
199 |
+
"JAK/STAT, PI3K/AKT, MAPK/ERK",
|
200 |
+
"Chronic myeloid leukemia, acute lymphoblastic leukemia"
|
201 |
+
],
|
202 |
+
"Valdecoxib": [
|
203 |
+
"COX-2 enzyme",
|
204 |
+
"Prostaglandin synthesis, pain signaling, inflammation",
|
205 |
+
"Osteoarthritis, rheumatoid arthritis, menstrual cramps, management of acute pain"
|
206 |
+
],
|
207 |
+
"Ouabain (Octahydrate)": [
|
208 |
+
"Na+/K+-ATPase",
|
209 |
+
"Cardiac glycoside signaling, ion transport, cellular respiration",
|
210 |
+
"Atrial fibrillation, atrial flutter, congestive heart failure"
|
211 |
+
],
|
212 |
+
"Oxaliplatin": [
|
213 |
+
"DNA",
|
214 |
+
"Apoptosis, cell cycle arrest, DNA damage response",
|
215 |
+
"Colorectal cancer, adjuvant treatment of stage III colon cancer, advanced colorectal cancer"
|
216 |
+
],
|
217 |
+
"Apalutamide": [
|
218 |
+
"Androgen receptor",
|
219 |
+
"Cell cycle regulation, apoptosis, DNA repair, angiogenesis",
|
220 |
+
"Non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer"
|
221 |
+
],
|
222 |
+
"Rapamycin": [
|
223 |
+
"mTOR",
|
224 |
+
"PI3K/AKT, MAPK/ERK, HIF-1\u03b1",
|
225 |
+
"Renal cell carcinoma, lymphangioleiomyomatosis, prophylaxis of organ transplant rejection"
|
226 |
+
],
|
227 |
+
"Altretamine": [
|
228 |
+
"DNA",
|
229 |
+
"Apoptosis, DNA damage response, cell cycle regulation",
|
230 |
+
"Ovarian cancer"
|
231 |
+
],
|
232 |
+
"Cinacalcet": [
|
233 |
+
"Calcimimetic receptor, calcium-sensing receptor",
|
234 |
+
"Phospholipase C pathway, mitogen-activated protein kinase pathway, adenylate cyclase pathway",
|
235 |
+
"Secondary hyperparathyroidism, hypercalcemia in parathyroid carcinoma, hypercalcemia in patients with chronic kidney disease on dialysis"
|
236 |
+
],
|
237 |
+
"Afatinib": [
|
238 |
+
"EGFR, HER2, HER4",
|
239 |
+
"PI3K/AKT, RAS/RAF/MAPK, JAK/STAT",
|
240 |
+
"Non-small cell lung cancer, squamous non-small cell lung cancer"
|
241 |
+
],
|
242 |
+
"Methylthiouracil": [
|
243 |
+
"Thyroid peroxidase, deiodinases",
|
244 |
+
"Thyroid hormone synthesis, hypothalamic-pituitary-thyroid axis",
|
245 |
+
"Hyperthyroidism, Graves' disease"
|
246 |
+
],
|
247 |
+
"Irinotecan (hydrochloride)": [
|
248 |
+
"Topoisomerase I",
|
249 |
+
"DNA replication, cell cycle arrest, apoptosis",
|
250 |
+
"Colorectal cancer, small cell lung cancer"
|
251 |
+
],
|
252 |
+
"Clotrimazole": [
|
253 |
+
"Lanosterol 14\u03b1-demethylase",
|
254 |
+
"Ergosterol biosynthesis, cell membrane integrity, fungal cell growth",
|
255 |
+
"Vaginal yeast infections, cutaneous candidiasis, tinea pedis, tinea cruris, tinea corporis"
|
256 |
+
],
|
257 |
+
"Erythromycin": [
|
258 |
+
"50S ribosomal subunit",
|
259 |
+
"Protein synthesis, cell growth, and division",
|
260 |
+
"Respiratory tract infections, skin and soft tissue infections, genital infections, Legionnaires' disease"
|
261 |
+
],
|
262 |
+
"Raltitrexed": [
|
263 |
+
"Thymidylate synthase",
|
264 |
+
"DNA synthesis, folate metabolism, cell cycle regulation",
|
265 |
+
"Colorectal cancer, pancreatic cancer"
|
266 |
+
],
|
267 |
+
"Infigratinib": [
|
268 |
+
"FGFR1, FGFR2, FGFR3",
|
269 |
+
"MAPK signaling, PI3K/AKT signaling, JAK/STAT signaling",
|
270 |
+
"Cholangiocarcinoma, Urothelial carcinoma"
|
271 |
+
],
|
272 |
+
"Cytarabine (hydrochloride)": [
|
273 |
+
"DNA polymerase, ribonucleotide reductase, DNA primase",
|
274 |
+
"Nucleotide metabolism, DNA synthesis, cell cycle regulation",
|
275 |
+
"Acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, meningitis"
|
276 |
+
],
|
277 |
+
"Daidzin": [
|
278 |
+
"Daidzin binds to acetaldehyde dehydrogenase 2, aldehyde dehydrogenase, mitochondrial aldehyde dehydrogenase, cytochrome P450 2E1",
|
279 |
+
"Alcohol dependence pathway, dopamine signaling pathway, glutamate signaling pathway, neuroinflammation pathway",
|
280 |
+
"Alcohol dependence, alcohol withdrawal syndrome, alcoholic liver disease"
|
281 |
+
],
|
282 |
+
"Rutin (trihydrate)": [
|
283 |
+
"Cyclooxygenase, Lipoxygenase, Phosphodiesterase, Protein kinase C",
|
284 |
+
"Inflammation, Oxidative stress, Cell signaling, Vascular tone regulation",
|
285 |
+
"Capillary fragility, Edema, Varicose veins, Venous insufficiency"
|
286 |
+
],
|
287 |
+
"AZD1390": [
|
288 |
+
"ATM kinase",
|
289 |
+
"DNA damage response, cell cycle checkpoint regulation, apoptosis",
|
290 |
+
"Treatment of unresectable or metastatic malignant solid tumors with ATM deficiency"
|
291 |
+
],
|
292 |
+
"Posaconazole": [
|
293 |
+
"Lanosterol 14\u03b1-demethylase",
|
294 |
+
"Ergosterol biosynthesis, cell membrane integrity",
|
295 |
+
"Invasive aspergillosis, oropharyngeal candidiasis, candidemia"
|
296 |
+
],
|
297 |
+
"Fumaric acid": [
|
298 |
+
"Nrf2, NF-\u03baB, STAT1, STAT3",
|
299 |
+
"Antioxidant response, Inflammation, Cell proliferation",
|
300 |
+
"Psoriasis, Multiple sclerosis"
|
301 |
+
],
|
302 |
+
"Ixazomib": [
|
303 |
+
"Proteasome",
|
304 |
+
"NF-\u03baB signaling, cell cycle regulation, apoptosis",
|
305 |
+
"Multiple myeloma"
|
306 |
+
],
|
307 |
+
"Busulfan": [
|
308 |
+
"DNA",
|
309 |
+
"Cell cycle regulation, DNA replication and repair, apoptosis",
|
310 |
+
"Chronic myelogenous leukemia, bone marrow ablation prior to hematopoietic stem cell transplantation"
|
311 |
+
],
|
312 |
+
"Mifepristone": [
|
313 |
+
"Progesterone receptor, glucocorticoid receptor",
|
314 |
+
"Apoptosis, cell cycle regulation, cortisol signaling",
|
315 |
+
"Cushing's syndrome, abortion, pregnancy termination"
|
316 |
+
],
|
317 |
+
"Phenylephrine (hydrochloride)": [
|
318 |
+
"Alpha-1 adrenergic receptors",
|
319 |
+
"Vasoconstriction, blood pressure regulation, smooth muscle contraction",
|
320 |
+
"Nasal decongestion, ophthalmic procedures, vascular failure, shock"
|
321 |
+
],
|
322 |
+
"Pimozide": [
|
323 |
+
"Dopamine D2 and D3 receptors, serotonin 5-HT2A receptors",
|
324 |
+
"Dopaminergic, serotonergic, and neuroendocrine signaling pathways",
|
325 |
+
"Tourette's syndrome, schizophrenia, and other psychotic disorders"
|
326 |
+
],
|
327 |
+
"Pravastatin (sodium)": [
|
328 |
+
"HMG-CoA reductase",
|
329 |
+
"Mevalonate pathway, cholesterol biosynthesis, lipid metabolism",
|
330 |
+
"Hyperlipidemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, prevention of cardiovascular events"
|
331 |
+
],
|
332 |
+
"Carbamazepine": [
|
333 |
+
"Voltage-gated sodium channels, NMDA receptors",
|
334 |
+
"GABAergic signaling, glutamatergic signaling, neuronal excitability",
|
335 |
+
"Epilepsy, trigeminal neuralgia, bipolar disorder"
|
336 |
+
],
|
337 |
+
"Roxadustat": [
|
338 |
+
"HIF-2\u03b1",
|
339 |
+
"Erythropoiesis, angiogenesis, inflammation",
|
340 |
+
"Anemia in chronic kidney disease patients on dialysis, anemia in chronic kidney disease patients not on dialysis"
|
341 |
+
],
|
342 |
+
"Dihydroartemisinin": [
|
343 |
+
"PfATP6, SERCA",
|
344 |
+
"Apoptosis, Autophagy, Cell cycle arrest, Oxidative stress",
|
345 |
+
"Malaria"
|
346 |
+
],
|
347 |
+
"Aspirin": [
|
348 |
+
"COX-1, COX-2",
|
349 |
+
"Prostaglandin synthesis, platelet aggregation, inflammation",
|
350 |
+
"Pain relief, fever reduction, inflammation reduction, cardiovascular disease prevention"
|
351 |
+
],
|
352 |
+
"Vitamin K4": [
|
353 |
+
"Gamma-glutamyl carboxylase, Vitamin K epoxide reductase, Vitamin K-dependent carboxylase",
|
354 |
+
"Blood coagulation, Bone metabolism, Cardiovascular health",
|
355 |
+
"Bleeding diathesis, Hypoprothrombinemia, Vitamin K deficiency"
|
356 |
+
],
|
357 |
+
"Digitoxin": [
|
358 |
+
"Na+/K+-ATPase",
|
359 |
+
"Cardiac conduction, renin-angiotensin-aldosterone system, intracellular calcium signaling",
|
360 |
+
"Atrial fibrillation, atrial flutter, congestive heart failure"
|
361 |
+
],
|
362 |
+
"Norepinephrine (hydrochloride)": [
|
363 |
+
"Alpha-1 adrenergic receptors, Alpha-2 adrenergic receptors, Beta-1 adrenergic receptors",
|
364 |
+
"Vasoconstriction pathway, Cardiac contractility pathway, Vasopressor pathway",
|
365 |
+
"Hypotension, Septic shock, Cardiac arrest"
|
366 |
+
],
|
367 |
+
"Megestrol": [
|
368 |
+
"Progesterone receptor",
|
369 |
+
"Glucocorticoid-mediated signaling, insulin-like growth factor-1 signaling, protein synthesis pathways",
|
370 |
+
"Anorexia, cachexia, and unexplained weight loss in patients with AIDS, breast cancer, and endometrial carcinoma"
|
371 |
+
],
|
372 |
+
"Irinotecan": [
|
373 |
+
"Topoisomerase I",
|
374 |
+
"DNA replication, cell cycle arrest, apoptosis",
|
375 |
+
"Colorectal cancer, small cell lung cancer"
|
376 |
+
],
|
377 |
+
"Trametinib (DMSO_TF solvate)": [
|
378 |
+
"MEK1, MEK2",
|
379 |
+
"MAPK/ERK signaling, PI3K/AKT signaling, cell cycle regulation",
|
380 |
+
"Metastatic melanoma, non-small cell lung cancer, thyroid cancer"
|
381 |
+
],
|
382 |
+
"Balsalazide (sodium hydrate)": [
|
383 |
+
"Azoreductases, bacterial beta-glucosidases",
|
384 |
+
"Inflammation reduction, antioxidant, prostaglandin synthesis",
|
385 |
+
"Ulcerative colitis"
|
386 |
+
],
|
387 |
+
"IQ 1": [
|
388 |
+
"PI3K, AKT, mTOR",
|
389 |
+
"Apoptosis, cell cycle regulation, angiogenesis",
|
390 |
+
"Breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors"
|
391 |
+
],
|
392 |
+
"Lucanthone": [
|
393 |
+
"DNA, topoisomerase II, protein kinase C",
|
394 |
+
"Apoptosis, cell cycle regulation, DNA replication",
|
395 |
+
"Schistosomiasis, intestinal amoebiasis"
|
396 |
+
],
|
397 |
+
"Temsirolimus": [
|
398 |
+
"mTOR",
|
399 |
+
"PI3K/AKT, cell cycle regulation, apoptosis",
|
400 |
+
"Advanced renal cell carcinoma"
|
401 |
+
],
|
402 |
+
"Dapagliflozin": [
|
403 |
+
"Sodium-glucose cotransporter 2 (SGLT2)",
|
404 |
+
"Glucose uptake, insulin sensitivity, renal glucose excretion, blood pressure regulation",
|
405 |
+
"Type 2 diabetes, heart failure, chronic kidney disease"
|
406 |
+
],
|
407 |
+
"TAK-901": [
|
408 |
+
"Sphingosine-1-phosphate receptor, LPA1 receptor",
|
409 |
+
"Phospholipase C pathway, Rho kinase pathway, PI3K/Akt pathway",
|
410 |
+
"Treatment of multiple sclerosis, treatment of ulcerative colitis"
|
411 |
+
],
|
412 |
+
"Larotrectinib": [
|
413 |
+
"NTRK1, NTRK2, NTRK3",
|
414 |
+
"MAPK, PI3K/AKT, NF-\u03baB",
|
415 |
+
"Solid tumors with NTRK fusion, infantile fibrosarcoma, thyroid cancer, salivary gland cancer"
|
416 |
+
],
|
417 |
+
"Gallic acid": [
|
418 |
+
"Estrogen receptors, COX-2, NF-\u03baB, STAT3, PI3K/AKT",
|
419 |
+
"Apoptosis, cell cycle regulation, inflammation, antioxidant defense",
|
420 |
+
"Wound healing, gastrointestinal disorders, cancer prevention"
|
421 |
+
],
|
422 |
+
"palbociclib": [
|
423 |
+
"CDK4, CDK6",
|
424 |
+
"Cell cycle progression, DNA replication, retinoblastoma protein regulation",
|
425 |
+
"HR-positive, HER2-negative advanced or metastatic breast cancer, HR-positive, HER2-negative metastatic breast cancer"
|
426 |
+
],
|
427 |
+
"Ciclopirox": [
|
428 |
+
"DNA, cytochrome P450, iron-sulfur proteins",
|
429 |
+
"Cellular respiration, fatty acid synthesis, sterol biosynthesis",
|
430 |
+
"Seborrheic dermatitis, cutaneous candidiasis, tinea pedis, tinea cruris, tinea corporis"
|
431 |
+
],
|
432 |
+
"Cysteamine (hydrochloride)": [
|
433 |
+
"Cystine transporter, lysosomal cystine transporter",
|
434 |
+
"Transcriptional regulation, lysosomal function, cellular autophagy",
|
435 |
+
"Cystinosis, nephropathic cystinosis"
|
436 |
+
],
|
437 |
+
"Pimitespib": [
|
438 |
+
"Heat shock protein 90 (HSP90)",
|
439 |
+
"Apoptosis, cell cycle regulation, angiogenesis",
|
440 |
+
"None, currently in clinical trials for various cancers"
|
441 |
+
],
|
442 |
+
"9-ING-41": [
|
443 |
+
"GSK3, TBK1",
|
444 |
+
"NF-\u03baB, PI3K/AKT, WNT/\u03b2-catenin",
|
445 |
+
"Triple-negative breast cancer, metastatic colorectal cancer, ovarian cancer"
|
446 |
+
],
|
447 |
+
"Citalopram (hydrobromide)": [
|
448 |
+
"Serotonin transporter",
|
449 |
+
"Neurotransmission, synaptic plasticity, mood regulation",
|
450 |
+
"Major depressive disorder, depressive episodes"
|
451 |
+
],
|
452 |
+
"Lopinavir": [
|
453 |
+
"HIV-1 protease",
|
454 |
+
"PI3K/Akt, NF-\u03baB, MAPK/ERK",
|
455 |
+
"HIV-1 infection, AIDS"
|
456 |
+
],
|
457 |
+
"Erdafitinib": [
|
458 |
+
"FGFR1, FGFR2, FGFR3, FGFR4",
|
459 |
+
"PI3K/AKT, RAS/MAPK, JAK/STAT",
|
460 |
+
"Locally advanced or metastatic urothelial carcinoma"
|
461 |
+
],
|
462 |
+
"Vortioxetine": [
|
463 |
+
"Serotonin receptors, serotonin transporter, norepinephrine transporter, GABA receptors, glutamate receptors",
|
464 |
+
"Neuroplasticity pathways, synaptic transmission, neuronal excitability, stress response",
|
465 |
+
"Major depressive disorder, generalized anxiety disorder, treatment-resistant depression"
|
466 |
+
],
|
467 |
+
"Tofacitinib": [
|
468 |
+
"JAK1, JAK2, JAK3, TYK2",
|
469 |
+
"JAK-STAT signaling, NF-\u03baB signaling, PI3K/AKT signaling",
|
470 |
+
"Rheumatoid arthritis, Psoriatic arthritis, Ulcerative colitis, Polyarticular juvenile idiopathic arthritis"
|
471 |
+
],
|
472 |
+
"Cilostazol": [
|
473 |
+
"Phosphodiesterase 3",
|
474 |
+
"Cyclic adenosine monophosphate signaling, platelet aggregation, vascular smooth muscle relaxation",
|
475 |
+
"Intermittent claudication, peripheral arterial disease"
|
476 |
+
],
|
477 |
+
"Verteporfin": [
|
478 |
+
"Protoporphyrin IX, YAP/TAZ, PD-L1",
|
479 |
+
"PI3K/AKT, NF-\u03baB, JAK/STAT, apoptosis",
|
480 |
+
"Age-related macular degeneration, pathological myopia, ocular histoplasmosis syndrome"
|
481 |
+
],
|
482 |
+
"Sapanisertib": [
|
483 |
+
"mTOR",
|
484 |
+
"PI3K/AKT, MAPK/ERK, HIF-1\u03b1",
|
485 |
+
"None"
|
486 |
+
],
|
487 |
+
"Retinoic acid": [
|
488 |
+
"Retinoic acid receptors (RARs), retinoid X receptors (RXRs)",
|
489 |
+
"Cell differentiation, apoptosis, inflammation, angiogenesis",
|
490 |
+
"Acute promyelocytic leukemia, severe cystic acne"
|
491 |
+
],
|
492 |
+
"Harringtonine": [
|
493 |
+
"Ribosomes",
|
494 |
+
"Protein synthesis, cell cycle regulation, apoptosis",
|
495 |
+
"Leukemia, lymphoma"
|
496 |
+
],
|
497 |
+
"Sivelestat (sodium tetrahydrate)": [
|
498 |
+
"Neutrophil elastase",
|
499 |
+
"Acute inflammatory response, coagulation cascade, oxidative stress",
|
500 |
+
"Acute respiratory distress syndrome"
|
501 |
+
],
|
502 |
+
"ML264": [
|
503 |
+
"ROR\u03b3t",
|
504 |
+
"Inflammation, immune response, cell differentiation",
|
505 |
+
"Psoriatic arthritis, psoriasis, rheumatoid arthritis"
|
506 |
+
],
|
507 |
+
"venetoclax": [
|
508 |
+
"BCL-2",
|
509 |
+
"Apoptosis, mitochondrial outer membrane permeabilization, intrinsic pathway of apoptosis",
|
510 |
+
"Chronic lymphocytic leukemia, acute myeloid leukemia, follicular lymphoma"
|
511 |
+
],
|
512 |
+
"Benztropine (mesylate)": [
|
513 |
+
"Muscarinic acetylcholine receptors",
|
514 |
+
"Dopaminergic signaling, cholinergic neurotransmission",
|
515 |
+
"Parkinsonian tremor, extrapyramidal symptoms, drug-induced parkinsonism"
|
516 |
+
],
|
517 |
+
"olaparib": [
|
518 |
+
"PARP1, PARP2",
|
519 |
+
"DNA repair, homologous recombination, base excision repair",
|
520 |
+
"Ovarian cancer, breast cancer, pancreatic cancer, prostate cancer"
|
521 |
+
],
|
522 |
+
"Budesonide": [
|
523 |
+
"Glucocorticoid receptor",
|
524 |
+
"Inflammation reduction, immune response suppression, apoptosis regulation",
|
525 |
+
"Asthma, chronic obstructive pulmonary disease, allergic rhinitis, Crohn's disease, ulcerative colitis"
|
526 |
+
],
|
527 |
+
"Macitentan": [
|
528 |
+
"Endothelin receptors",
|
529 |
+
"Endothelin-1 signaling, vascular remodeling, proliferation",
|
530 |
+
"Pulmonary arterial hypertension"
|
531 |
+
],
|
532 |
+
"Dexmedetomidine": [
|
533 |
+
"Alpha-2 adrenergic receptors",
|
534 |
+
"Sympathetic nervous system activity, sedation pathways, analgesic pathways",
|
535 |
+
"Sedation in intensive care unit patients, sedation for procedural sedation, agitation in intensive care unit patients"
|
536 |
+
],
|
537 |
+
"Phenytoin (sodium)": [
|
538 |
+
"Voltage-gated sodium channels",
|
539 |
+
"Inhibition of neuronal excitability, reduction of post-tetanic potentiation, blockade of synaptic transmission",
|
540 |
+
"Seizures, status epilepticus, tonic-clonic seizures, complex partial seizures"
|
541 |
+
],
|
542 |
+
"Procainamide (hydrochloride)": [
|
543 |
+
"Sodium channels, potassium channels",
|
544 |
+
"Cardiac action potential, atrioventricular node conduction, ventricular depolarization",
|
545 |
+
"Life-threatening ventricular arrhythmias, atrial fibrillation, supraventricular tachycardia"
|
546 |
+
],
|
547 |
+
"Eplerenone": [
|
548 |
+
"Mineralocorticoid receptor",
|
549 |
+
"Aldosterone-sensitive sodium transport, blood pressure regulation, cardiac fibrosis",
|
550 |
+
"Hypertension, heart failure, primary aldosteronism"
|
551 |
+
],
|
552 |
+
"Pentamidine (isethionate)": [
|
553 |
+
"P2X purinoceptor 7, DNA",
|
554 |
+
"Inflammation, apoptosis, cellular stress response",
|
555 |
+
"Pneumocystis pneumonia, trypanosomiasis"
|
556 |
+
],
|
557 |
+
"Ponatinib": [
|
558 |
+
"BCR-ABL, FGFR, VEGFR, PDGFR",
|
559 |
+
"MAPK, PI3K/AKT, JAK/STAT, angiogenesis",
|
560 |
+
"Chronic myeloid leukemia, acute lymphoblastic leukemia"
|
561 |
+
],
|
562 |
+
"Salicylic acid": [
|
563 |
+
"COX-1, COX-2, NF-\u03baB",
|
564 |
+
"Inflammation, pain, fever, apoptosis",
|
565 |
+
"Acne, psoriasis, calluses, corns, warts"
|
566 |
+
],
|
567 |
+
"Bicalutamide": [
|
568 |
+
"Androgen receptor",
|
569 |
+
"Cell proliferation, apoptosis, angiogenesis, steroidogenesis",
|
570 |
+
"Prostate cancer"
|
571 |
+
],
|
572 |
+
"Folic acid": [
|
573 |
+
"Dihydrofolate reductase, folate receptor",
|
574 |
+
"Methionine cycle, nucleotide synthesis, homocysteine metabolism",
|
575 |
+
"Megaloblastic anemia, fetal development during pregnancy, osteoporosis prevention"
|
576 |
+
],
|
577 |
+
"Torkinib": [
|
578 |
+
"MET, AXL, VEGFR2, TIE2",
|
579 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT, angiogenesis",
|
580 |
+
"Advanced renal cell carcinoma, hepatocellular carcinoma"
|
581 |
+
],
|
582 |
+
"Idoxuridine": [
|
583 |
+
"Thymidine kinase, DNA polymerase",
|
584 |
+
"Nucleotide synthesis, DNA replication, viral replication",
|
585 |
+
"Herpes simplex keratitis"
|
586 |
+
],
|
587 |
+
"Ivermectin": [
|
588 |
+
"Glutamate-gated chloride channels, gamma-aminobutyric acid (GABA) receptors, glycine receptors, P2X4 receptors",
|
589 |
+
"Mammalian target of rapamycin (mTOR) pathway, phosphoinositide 3-kinase (PI3K)/AKT pathway, nuclear factor-kappa B (NF-\u03baB) pathway",
|
590 |
+
"Onchocerciasis, strongyloidiasis, ascariasis, trichuriasis, enterobiasis, hookworm disease"
|
591 |
+
],
|
592 |
+
"Uridine": [
|
593 |
+
"Nucleoside transporters, RNA, DNA",
|
594 |
+
"Pyrimidine metabolism, glycolysis, mitochondrial function",
|
595 |
+
"Herpes simplex virus infections, cardiovascular disease, mitochondrial disorders"
|
596 |
+
],
|
597 |
+
"RMC-6236": [
|
598 |
+
"CD47, SIRP\u03b1",
|
599 |
+
"Phagocytosis, immune response, cell signaling",
|
600 |
+
"No approved indications"
|
601 |
+
],
|
602 |
+
"Elagolix sodium": [
|
603 |
+
"Gonadotropin-releasing hormone receptors",
|
604 |
+
"Hypothalamic-pituitary-gonadal axis, ovarian function regulation, luteinizing hormone and follicle-stimulating hormone secretion",
|
605 |
+
"Moderate to severe pain associated with endometriosis, heavy menstrual bleeding associated with uterine fibroids"
|
606 |
+
],
|
607 |
+
"S-Adenosyl-L-methionine (disulfate tosylate)": [
|
608 |
+
"Methionine adenosyltransferase, catechol-O-methyltransferase, histone methyltransferases, DNA methyltransferases",
|
609 |
+
"Methylation, transsulfuration, polyamine synthesis",
|
610 |
+
"Osteoarthritis, depression, liver disease"
|
611 |
+
],
|
612 |
+
"Meloxicam": [
|
613 |
+
"COX-1, COX-2",
|
614 |
+
"Prostaglandin synthesis, Inflammatory response, Pain perception",
|
615 |
+
"Osteoarthritis, Rheumatoid arthritis, Juvenile rheumatoid arthritis"
|
616 |
+
],
|
617 |
+
"Vilanterol": [
|
618 |
+
"Beta-2 adrenergic receptors",
|
619 |
+
"Airway smooth muscle relaxation, bronchodilation, inflammation reduction",
|
620 |
+
"Chronic obstructive pulmonary disease, asthma"
|
621 |
+
],
|
622 |
+
"vincristine": [
|
623 |
+
"Tubulin",
|
624 |
+
"Cell cycle arrest, apoptosis, and inhibition of microtubule dynamics",
|
625 |
+
"Acute lymphoblastic leukemia, lymphomas, childhood rhabdomyosarcoma, neuroblastoma, and Wilms' tumor"
|
626 |
+
],
|
627 |
+
"Carbidopa (monohydrate)": [
|
628 |
+
"Aromatic L-amino acid decarboxylase",
|
629 |
+
"Dopaminergic pathway, neurotransmitter synthesis",
|
630 |
+
"Parkinson's disease, restless legs syndrome"
|
631 |
+
],
|
632 |
+
"8-Hydroxyquinoline": [
|
633 |
+
"DNA, RNA, Proteins, Metals",
|
634 |
+
"Apoptosis, Cell cycle regulation, DNA replication",
|
635 |
+
"Antimalarial, Antiprotozoal, Antibacterial"
|
636 |
+
],
|
637 |
+
"Betamethasone dipropionate": [
|
638 |
+
"Glucocorticoid receptor",
|
639 |
+
"Inflammation reduction, immune response suppression, apoptosis regulation",
|
640 |
+
"Psoriasis, eczema, dermatitis, allergic contact dermatitis"
|
641 |
+
],
|
642 |
+
"Fusidic acid": [
|
643 |
+
"Elongation factor G",
|
644 |
+
"Protein synthesis, cell growth, and bacterial cell wall formation",
|
645 |
+
"Bacterial infections, osteomyelitis, septicemia, and infections caused by Staphylococcus aureus"
|
646 |
+
],
|
647 |
+
"Trimetrexate": [
|
648 |
+
"Dihydrofolate reductase",
|
649 |
+
"Methotrexate pathway, folate metabolism, nucleic acid synthesis",
|
650 |
+
"Pneumocystis jiroveci pneumonia"
|
651 |
+
],
|
652 |
+
"Silodosin": [
|
653 |
+
"Alpha-1 adrenergic receptors",
|
654 |
+
"Rho kinase pathway, smooth muscle contraction pathway, nitric oxide pathway",
|
655 |
+
"Benign prostatic hyperplasia, urinary retention, lower urinary tract symptoms"
|
656 |
+
],
|
657 |
+
"Abiraterone acetate": [
|
658 |
+
"CYP17",
|
659 |
+
"Androgen biosynthesis, glucocorticoid biosynthesis, steroidogenesis",
|
660 |
+
"Metastatic castration-resistant prostate cancer, metastatic high-risk castration-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer"
|
661 |
+
],
|
662 |
+
"Talc": [
|
663 |
+
"Mesothelial cells, macrophages, inflammatory mediators",
|
664 |
+
"Inflammation, fibrosis, coagulation",
|
665 |
+
"Malignant pleural effusion, recurrent pleural effusion"
|
666 |
+
],
|
667 |
+
"Cobimetinib": [
|
668 |
+
"MEK1, MEK2",
|
669 |
+
"MAPK/ERK signaling, cell cycle regulation, apoptosis",
|
670 |
+
"BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, hormone receptor-positive advanced or metastatic breast cancer"
|
671 |
+
],
|
672 |
+
"Goserelin (acetate)": [
|
673 |
+
"Gonadotropin-releasing hormone (GnRH) receptors",
|
674 |
+
"Hypothalamic-pituitary-gonadal axis, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) regulation",
|
675 |
+
"Prostate cancer, breast cancer, endometriosis, uterine fibroids, precocious puberty"
|
676 |
+
],
|
677 |
+
"Estrone sulfate (potassium)": [
|
678 |
+
"Estrogen receptors",
|
679 |
+
"Cell growth and differentiation, hormone regulation, menopause-related pathways",
|
680 |
+
"Menopausal symptoms, osteoporosis, vaginal atrophy"
|
681 |
+
],
|
682 |
+
"Arbutin": [
|
683 |
+
"Tyrosinase",
|
684 |
+
"Melanogenesis, antioxidant, anti-inflammatory",
|
685 |
+
"Hyperpigmentation, melasma, solar lentigines"
|
686 |
+
],
|
687 |
+
"Bisoprolol (hemifumarate)": [
|
688 |
+
"Beta-1 adrenergic receptors",
|
689 |
+
"Cardiac conduction, vascular smooth muscle contraction, renin-angiotensin-aldosterone system",
|
690 |
+
"Hypertension, angina pectoris, heart failure"
|
691 |
+
],
|
692 |
+
"Oleic acid": [
|
693 |
+
"PPAR\u03b3, GPR40, GPR119",
|
694 |
+
"Insulin signaling, fatty acid metabolism, inflammation",
|
695 |
+
"Wound healing, nutritional supplement"
|
696 |
+
],
|
697 |
+
"Berberine (chloride hydrate)": [
|
698 |
+
"AMP-activated protein kinase, DNA, protein kinase C, cyclooxygenase-2, aldose reductase",
|
699 |
+
"Insulin signaling pathway, NF-\u03baB pathway, PI3K/Akt pathway, mitochondrial biogenesis pathway",
|
700 |
+
"Type 2 diabetes, dyslipidemia, gastrointestinal infections"
|
701 |
+
],
|
702 |
+
"Edoxaban (tosylate monohydrate)": [
|
703 |
+
"Factor Xa",
|
704 |
+
"Coagulation cascade, thrombin generation",
|
705 |
+
"Non-valvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, stroke prevention"
|
706 |
+
],
|
707 |
+
"Bendamustine": [
|
708 |
+
"DNA, histone proteins",
|
709 |
+
"Apoptosis, cell cycle regulation, DNA damage response",
|
710 |
+
"Chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma"
|
711 |
+
],
|
712 |
+
"Adagrasib": [
|
713 |
+
"KRAS G12C",
|
714 |
+
"MAPK, PI3K/AKT, RAS/RAF signaling",
|
715 |
+
"Non-small cell lung cancer, colorectal cancer"
|
716 |
+
],
|
717 |
+
"OTS514": [
|
718 |
+
"CDK2, CDK4, CDK6, CDK9",
|
719 |
+
"Cell cycle progression, DNA replication, Transcriptional regulation",
|
720 |
+
"Breast cancer, Lung cancer, Melanoma"
|
721 |
+
],
|
722 |
+
"Tazarotene": [
|
723 |
+
"Retinoic acid receptors (RARs), retinoid X receptors (RXRs)",
|
724 |
+
"Cell differentiation, apoptosis, inflammation, keratinization",
|
725 |
+
"Psoriasis, acne, fine wrinkles, facial lentigines, hyperpigmentation"
|
726 |
+
],
|
727 |
+
"Pexidartinib (hydrochloride)": [
|
728 |
+
"CSF1R, KIT, FLT3, VEGFR, PDGFR",
|
729 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT, angiogenesis",
|
730 |
+
"Tenosynovial giant cell tumor, giant cell tumor of the tendon sheath, pigmented villonodular synovitis"
|
731 |
+
],
|
732 |
+
"Finasteride": [
|
733 |
+
"5-alpha-reductase",
|
734 |
+
"Androgen biosynthesis, hair growth regulation, prostate growth regulation",
|
735 |
+
"Benign prostatic hyperplasia, male pattern hair loss, prostate cancer"
|
736 |
+
],
|
737 |
+
"Bimatoprost": [
|
738 |
+
"Prostaglandin F2 alpha receptor",
|
739 |
+
"Intraocular pressure reduction, aqueous humor outflow, uveoscleral outflow",
|
740 |
+
"Glaucoma, ocular hypertension, eyelash hypotrichosis"
|
741 |
+
],
|
742 |
+
"Homoharringtonine": [
|
743 |
+
"Ribosomes",
|
744 |
+
"Protein synthesis, cell cycle regulation, apoptosis",
|
745 |
+
"Chronic myeloid leukemia, myelofibrosis, other myeloproliferative neoplasms"
|
746 |
+
],
|
747 |
+
"BI-3406": [
|
748 |
+
"TNFR2, CD40, HVEM",
|
749 |
+
"NF-\u03baB signaling, cell survival, immune response",
|
750 |
+
"Non-Hodgkin's lymphoma, chronic lymphocytic leukemia"
|
751 |
+
],
|
752 |
+
"Ipatasertib": [
|
753 |
+
"AKT, PI3K, PDK1, mTOR",
|
754 |
+
"PI3K/AKT signaling, cell cycle regulation, apoptosis",
|
755 |
+
"None"
|
756 |
+
],
|
757 |
+
"Temuterkib": [
|
758 |
+
"ERK1, ERK2",
|
759 |
+
"MAPK signaling, cell cycle regulation, apoptosis",
|
760 |
+
"Non-small cell lung cancer, solid tumors"
|
761 |
+
],
|
762 |
+
"Lidocaine (hydrochloride)": [
|
763 |
+
"Sodium channels, voltage-gated calcium channels",
|
764 |
+
"Pain transmission, inflammatory response, sympathetic nervous system activity",
|
765 |
+
"Local anesthesia, ventricular arrhythmias, trigeminal neuralgia"
|
766 |
+
],
|
767 |
+
"Trametinib": [
|
768 |
+
"MEK1, MEK2",
|
769 |
+
"MAPK/ERK, PI3K/AKT, NF-\u03baB",
|
770 |
+
"Melanoma, Non-small cell lung cancer, Thyroid cancer"
|
771 |
+
],
|
772 |
+
"Mebendazole": [
|
773 |
+
"Tubulin",
|
774 |
+
"Microtubule dynamics, cell division, glucose uptake",
|
775 |
+
"Hookworm infections, roundworm infections, pinworm infections, whipworm infections, trichuriasis, neurocysticercosis, hydatid disease, echinococcosis"
|
776 |
+
],
|
777 |
+
"Pasireotide (acetate)": [
|
778 |
+
"Somatostatin receptors 1, 2, 3, and 5",
|
779 |
+
"Cell proliferation signaling, hormone secretion regulation, apoptosis modulation, angiogenesis inhibition",
|
780 |
+
"Cushing's disease, acromegaly"
|
781 |
+
],
|
782 |
+
"Perindopril (erbumine)": [
|
783 |
+
"Angiotensin-converting enzyme (ACE)",
|
784 |
+
"Renin-angiotensin-aldosterone system, blood pressure regulation, vascular remodeling",
|
785 |
+
"Hypertension, stable coronary artery disease, heart failure"
|
786 |
+
],
|
787 |
+
"Brivudine": [
|
788 |
+
"Herpes simplex virus thymidine kinase, viral DNA polymerase",
|
789 |
+
"Nucleotide synthesis, viral replication, cell proliferation",
|
790 |
+
"Herpes zoster, herpes simplex"
|
791 |
+
],
|
792 |
+
"Thymopentin": [
|
793 |
+
"T cells, thymus-derived lymphocytes",
|
794 |
+
"Immune response, cell-mediated immunity, inflammatory response",
|
795 |
+
"Immunodeficiency, rheumatoid arthritis, systemic lupus erythematosus"
|
796 |
+
],
|
797 |
+
"Trifluridine": [
|
798 |
+
"Thymidylate synthase, DNA",
|
799 |
+
"Nucleotide synthesis, DNA replication, cell cycle progression",
|
800 |
+
"Metastatic colorectal cancer, metastatic gastric cancer"
|
801 |
+
],
|
802 |
+
"DT-061": [
|
803 |
+
"CDK2, CDK4, CDK6",
|
804 |
+
"Cell cycle regulation, DNA replication, apoptosis",
|
805 |
+
"Breast cancer, ovarian cancer, non-small cell lung cancer"
|
806 |
+
],
|
807 |
+
"Methyl aminolevulinate (hydrochloride)": [
|
808 |
+
"Protoporphyrin IX",
|
809 |
+
"Apoptosis, cell cycle arrest, mitochondrial damage",
|
810 |
+
"Actinic keratosis, Bowen's disease, basal cell carcinoma"
|
811 |
+
],
|
812 |
+
"Gemfibrozil": [
|
813 |
+
"Peroxisome proliferator-activated receptor alpha (PPAR\u03b1)",
|
814 |
+
"Lipid metabolism, fatty acid oxidation, triglyceride clearance",
|
815 |
+
"Hyperlipidemia, mixed dyslipidemia, elevated triglycerides, low HDL cholesterol"
|
816 |
+
],
|
817 |
+
"Clonidine (hydrochloride)": [
|
818 |
+
"Alpha-2 adrenergic receptors",
|
819 |
+
"Sympathetic nervous system signaling, blood vessel constriction, neurotransmitter release",
|
820 |
+
"Hypertension, attention deficit hyperactivity disorder, pain management, anxiety and agitation"
|
821 |
+
],
|
822 |
+
"Neratinib (maleate)": [
|
823 |
+
"ErbB2, ErbB4, EGFR",
|
824 |
+
"PI3K/AKT, MAPK/ERK, cell cycle regulation",
|
825 |
+
"Extended adjuvant treatment of early-stage HER2-positive breast cancer, metastatic HER2-positive breast cancer"
|
826 |
+
],
|
827 |
+
"Canagliflozin": [
|
828 |
+
"Sodium-glucose cotransporter 2 (SGLT2)",
|
829 |
+
"Glucose reabsorption, insulin sensitivity, glucagon secretion, blood pressure regulation",
|
830 |
+
"Type 2 diabetes mellitus, heart failure, chronic kidney disease"
|
831 |
+
],
|
832 |
+
"Naproxen": [
|
833 |
+
"COX-1, COX-2",
|
834 |
+
"Prostaglandin synthesis, Inflammatory response, Pain perception",
|
835 |
+
"Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis, Dysmenorrhea, Pain management"
|
836 |
+
],
|
837 |
+
"Tetracycline (hydrochloride)": [
|
838 |
+
"30S ribosomal subunit",
|
839 |
+
"Protein synthesis, cell growth, apoptosis",
|
840 |
+
"Acne, Rocky Mountain spotted fever, brucellosis, cholera, plague, malaria, syphilis, gonorrhea"
|
841 |
+
],
|
842 |
+
"5-Azacytidine": [
|
843 |
+
"DNA methyltransferase, DNMT1, DNMT3A, DNMT3B",
|
844 |
+
"Cell cycle regulation, DNA demethylation, apoptosis, autophagy",
|
845 |
+
"Myelodysplastic syndromes, acute myeloid leukemia, chronic myelomonocytic leukemia"
|
846 |
+
],
|
847 |
+
"Omeprazole": [
|
848 |
+
"H+/K+ ATPase",
|
849 |
+
"Proton pump inhibition, gastric acid secretion, hormone regulation",
|
850 |
+
"Gastroesophageal reflux disease, Zollinger-Ellison syndrome, peptic ulcer disease, Helicobacter pylori infection"
|
851 |
+
],
|
852 |
+
"Sildenafil": [
|
853 |
+
"Phosphodiesterase type 5 (PDE5)",
|
854 |
+
"Nitric oxide signaling, cyclic guanosine monophosphate (cGMP) signaling, smooth muscle relaxation",
|
855 |
+
"Erectile dysfunction, pulmonary arterial hypertension, exercise-induced pulmonary hypertension"
|
856 |
+
],
|
857 |
+
"Vismodegib": [
|
858 |
+
"Smoothened",
|
859 |
+
"Hedgehog signaling pathway, cell cycle regulation, apoptosis",
|
860 |
+
"Basal cell carcinoma"
|
861 |
+
],
|
862 |
+
"Cyclosporin A": [
|
863 |
+
"Calcineurin, cyclophilin",
|
864 |
+
"NF-AT signaling, T-cell activation, immune response",
|
865 |
+
"Organ rejection in kidney, liver, and heart transplants, rheumatoid arthritis, psoriasis, nephrotic syndrome"
|
866 |
+
],
|
867 |
+
"PH-797804": [
|
868 |
+
"p38 mitogen-activated protein kinase (p38 MAPK)",
|
869 |
+
"NF-\u03baB signaling, cytokine production, inflammatory responses",
|
870 |
+
"Moderate to severe plaque psoriasis, rheumatoid arthritis, psoriatic arthritis"
|
871 |
+
],
|
872 |
+
"Sodium Salicylate": [
|
873 |
+
"COX-1, COX-2, NF-\u03baB",
|
874 |
+
"Inflammatory response, pain signaling, fever regulation",
|
875 |
+
"Pain relief, fever reduction, rheumatic fever, osteoarthritis"
|
876 |
+
],
|
877 |
+
"Artemether": [
|
878 |
+
"PfATP6, parasite mitochondria",
|
879 |
+
"Apoptosis, cell cycle arrest, oxidative stress",
|
880 |
+
"Malaria, severe malaria, cerebral malaria"
|
881 |
+
],
|
882 |
+
"Peretinoin": [
|
883 |
+
"RAR\u03b1, RAR\u03b2, RAR\u03b3",
|
884 |
+
"Apoptosis, cell differentiation, lipid metabolism",
|
885 |
+
"Acute promyelocytic leukemia"
|
886 |
+
],
|
887 |
+
"Darolutamide": [
|
888 |
+
"Androgen receptor",
|
889 |
+
"Cell proliferation, apoptosis, angiogenesis, NF-\u03baB signaling",
|
890 |
+
"Non-metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer"
|
891 |
+
],
|
892 |
+
"Rimonabant (Hydrochloride)": [
|
893 |
+
"CB1 receptors",
|
894 |
+
"Lipid metabolism, glucose homeostasis, appetite regulation",
|
895 |
+
"Obesity, smoking cessation"
|
896 |
+
],
|
897 |
+
"LJI308": [
|
898 |
+
"PI3K, mTOR, Akt",
|
899 |
+
"Insulin/IGF-1 signaling, cell proliferation, apoptosis",
|
900 |
+
"Breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors"
|
901 |
+
],
|
902 |
+
"ULK-101": [
|
903 |
+
"ULK1, ULK2, ULK3",
|
904 |
+
"Autophagy, apoptosis, cell cycle regulation",
|
905 |
+
"Neurodegenerative diseases, cancer, infectious diseases"
|
906 |
+
],
|
907 |
+
"LY2090314": [
|
908 |
+
"CDK4, CDK6",
|
909 |
+
"PI3K/AKT, Rb, cell cycle regulation",
|
910 |
+
"Breast cancer, HR-positive, HER2-negative, advanced or metastatic"
|
911 |
+
],
|
912 |
+
"Berbamine (dihydrochloride)": [
|
913 |
+
"DNA topoisomerase II, protein tyrosine kinases",
|
914 |
+
"Apoptosis, cell cycle regulation, angiogenesis",
|
915 |
+
"Leukemia, lymphoma"
|
916 |
+
],
|
917 |
+
"Adenine": [
|
918 |
+
"Purine receptors, adenosine receptors, A1, A2A, A2B, A3",
|
919 |
+
"Inflammation, immune response, cardiovascular signaling, neurotransmission",
|
920 |
+
"No approved therapeutic indications"
|
921 |
+
],
|
922 |
+
"Proglumide": [
|
923 |
+
"Cholecystokinin receptors",
|
924 |
+
"Gastrointestinal motility, satiety signaling, pancreatic secretion",
|
925 |
+
"Peptic ulcer disease, gastroesophageal reflux disease"
|
926 |
+
],
|
927 |
+
"DTP3": [
|
928 |
+
"Diphtheria toxin, Pertussis toxin, Tetanus toxin",
|
929 |
+
"Cell signaling, Immune response, Neurotransmission",
|
930 |
+
"Diphtheria, Pertussis, Tetanus"
|
931 |
+
],
|
932 |
+
"Clopidogrel": [
|
933 |
+
"P2Y12 receptor",
|
934 |
+
"Platelet activation, aggregation, and blood coagulation pathways",
|
935 |
+
"Acute coronary syndrome, myocardial infarction, stroke, peripheral artery disease"
|
936 |
+
],
|
937 |
+
"Topotecan (hydrochloride)": [
|
938 |
+
"Topoisomerase I",
|
939 |
+
"DNA replication, cell cycle progression, apoptosis",
|
940 |
+
"Ovarian cancer, small cell lung cancer, cervical cancer"
|
941 |
+
],
|
942 |
+
"Tadalafil": [
|
943 |
+
"Phosphodiesterase type 5 (PDE5)",
|
944 |
+
"Nitric oxide signaling, cyclic guanosine monophosphate (cGMP) signaling, smooth muscle relaxation",
|
945 |
+
"Erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension"
|
946 |
+
],
|
947 |
+
"Ivabradine (hydrochloride)": [
|
948 |
+
"HCN channels",
|
949 |
+
"Cardiac conduction, sinoatrial node function, sympathetic activity",
|
950 |
+
"Angina pectoris, inappropriate sinus tachycardia, heart failure"
|
951 |
+
],
|
952 |
+
"Sunitinib": [
|
953 |
+
"VEGFRs, PDGFRs, KIT, FLT3, RET",
|
954 |
+
"Angiogenesis, cell proliferation, apoptosis, metastasis",
|
955 |
+
"Renal cell carcinoma, gastrointestinal stromal tumor, pancreatic neuroendocrine tumors"
|
956 |
+
],
|
957 |
+
"Nevirapine": [
|
958 |
+
"HIV-1 reverse transcriptase",
|
959 |
+
"NF-\u03baB signaling, cell cycle regulation, apoptosis",
|
960 |
+
"HIV-1 infection, AIDS"
|
961 |
+
],
|
962 |
+
"Hydroxyurea": [
|
963 |
+
"Ribonucleotide reductase",
|
964 |
+
"DNA synthesis, cell cycle regulation, nitric oxide production",
|
965 |
+
"Sickle cell disease, chronic myeloid leukemia, cancer, psoriasis"
|
966 |
+
],
|
967 |
+
"Doxorubicin (hydrochloride)": [
|
968 |
+
"DNA topoisomerase II, DNA",
|
969 |
+
"Apoptosis, cell cycle arrest, DNA damage response",
|
970 |
+
"Breast cancer, ovarian cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, Wilms tumor, neuroblastoma, soft tissue sarcoma, osteosarcoma"
|
971 |
+
],
|
972 |
+
"Omeprazole (sodium)": [
|
973 |
+
"H+/K+ ATPase",
|
974 |
+
"Proton pump inhibition, gastric acid secretion, mucosal defense",
|
975 |
+
"Gastroesophageal reflux disease, Zollinger-Ellison syndrome, peptic ulcer disease, Helicobacter pylori infection"
|
976 |
+
],
|
977 |
+
"Ataluren": [
|
978 |
+
"Nonsense mutations in mRNA",
|
979 |
+
"Protein synthesis, nonsense-mediated mRNA decay, cellular stress response",
|
980 |
+
"Duchenne muscular dystrophy, mucopolysaccharidosis type I"
|
981 |
+
],
|
982 |
+
"Flumatinib (mesylate)": [
|
983 |
+
"ABL, PDGFR, c-Kit",
|
984 |
+
"JAK/STAT, PI3K/AKT, MAPK/ERK",
|
985 |
+
"Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia"
|
986 |
+
],
|
987 |
+
"\u03b3-Oryzanol": [
|
988 |
+
"Cyclooxygenase-2, 5-lipoxygenase, nuclear factor-kappa B, peroxisome proliferator-activated receptor gamma",
|
989 |
+
"Inflammation, antioxidant, apoptosis, cell cycle regulation",
|
990 |
+
"Hyperlipidemia, menopausal symptoms, gastrointestinal disorders"
|
991 |
+
],
|
992 |
+
"Furosemide": [
|
993 |
+
"Na+/K+/2Cl- cotransporter",
|
994 |
+
"Renin-angiotensin-aldosterone system, sympathetic nervous system, prostaglandin synthesis",
|
995 |
+
"Edema, hypertension, pulmonary edema, ascites"
|
996 |
+
],
|
997 |
+
"Monocrotaline": [
|
998 |
+
"Endothelin receptors, phospholipase A2",
|
999 |
+
"Apoptosis, inflammation, vascular remodeling",
|
1000 |
+
"Pulmonary hypertension, hepatopulmonary syndrome"
|
1001 |
+
],
|
1002 |
+
"Doxycycline (monohydrate)": [
|
1003 |
+
"30S ribosomal subunit",
|
1004 |
+
"Protein synthesis, inflammation, apoptosis",
|
1005 |
+
"Periodontitis, acne, rocky mountain spotted fever, Lyme disease"
|
1006 |
+
],
|
1007 |
+
"Triclosan": [
|
1008 |
+
"Enoyl-acyl carrier protein reductase, FabI",
|
1009 |
+
"Fatty acid biosynthesis, cell membrane integrity",
|
1010 |
+
"Acne, dermatitis, gingivitis"
|
1011 |
+
],
|
1012 |
+
"PF-06260933": [
|
1013 |
+
"CD47, SIRP\u03b1",
|
1014 |
+
"Phagocytosis, immune response, cell signaling",
|
1015 |
+
"No approved indications"
|
1016 |
+
],
|
1017 |
+
"SBI-0640756": [
|
1018 |
+
"CSF1R, c-KIT",
|
1019 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
1020 |
+
"Rheumatoid arthritis, psoriasis, cancer"
|
1021 |
+
],
|
1022 |
+
"Acetohexamide": [
|
1023 |
+
"Pancreatic ATP-sensitive potassium channels, sulfonylurea receptor 1",
|
1024 |
+
"Insulin secretion pathway, glucose metabolism pathway, pancreatic beta-cell function pathway",
|
1025 |
+
"Type 2 diabetes mellitus"
|
1026 |
+
],
|
1027 |
+
"Pyridoxine": [
|
1028 |
+
"Pyridoxal phosphate, Pyridoxal kinase, GABA receptors, Kynureninase",
|
1029 |
+
"Glycogenolysis, Gluconeogenesis, Neurotransmitter synthesis, Hemoglobin synthesis",
|
1030 |
+
"Dietary supplement for pyridoxine deficiency, Vitamin B6 deficiency, Pyridoxine-dependent epilepsy, Homocystinuria, Sideroblastic anemia"
|
1031 |
+
],
|
1032 |
+
"Bexarotene": [
|
1033 |
+
"Retinoid X receptors (RXR)",
|
1034 |
+
"Cell differentiation, apoptosis, lipid metabolism, immune response",
|
1035 |
+
"Cutaneous T-cell lymphoma"
|
1036 |
+
],
|
1037 |
+
"Econazole": [
|
1038 |
+
"Lanosterol 14\u03b1-demethylase",
|
1039 |
+
"Sterol biosynthesis, cell membrane integrity, fungal cell growth",
|
1040 |
+
"Tinea pedis, tinea cruris, tinea corporis, cutaneous candidiasis, tinea versicolor"
|
1041 |
+
],
|
1042 |
+
"Imiquimod (hydrochloride)": [
|
1043 |
+
"Toll-like receptor 7 and 8",
|
1044 |
+
"Immune response, inflammatory response, cell death",
|
1045 |
+
"Actinic keratosis, superficial basal cell carcinoma, external genital and perianal warts"
|
1046 |
+
],
|
1047 |
+
"Everolimus": [
|
1048 |
+
"mTOR",
|
1049 |
+
"PI3K/AKT, cell cycle regulation, angiogenesis",
|
1050 |
+
"Renal cell carcinoma, breast cancer, pancreatic neuroendocrine tumors, advanced hepatocellular carcinoma, tuberous sclerosis complex"
|
1051 |
+
],
|
1052 |
+
"Plicamycin": [
|
1053 |
+
"DNA, ribonucleic acid",
|
1054 |
+
"Apoptosis, cell cycle arrest, bone resorption",
|
1055 |
+
"Testicular cancer, hypercalcemia, Paget's disease"
|
1056 |
+
],
|
1057 |
+
"Elimusertib hydrochloride": [
|
1058 |
+
"Aurora kinases",
|
1059 |
+
"Cell cycle regulation, apoptosis, angiogenesis",
|
1060 |
+
"None, currently in clinical trials for solid tumors and hematologic malignancies"
|
1061 |
+
],
|
1062 |
+
"Filgotinib": [
|
1063 |
+
"JAK1",
|
1064 |
+
"Cytokine signaling, immune cell activation, inflammation",
|
1065 |
+
"Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis"
|
1066 |
+
],
|
1067 |
+
"Tomivosertib": [
|
1068 |
+
"MNK1, MNK2",
|
1069 |
+
"MAPK, mTOR, PI3K/AKT",
|
1070 |
+
"None"
|
1071 |
+
],
|
1072 |
+
"Tofacitinib (citrate)": [
|
1073 |
+
"JAK1, JAK2, JAK3, TYK2",
|
1074 |
+
"JAK-STAT signaling, immune response, inflammation",
|
1075 |
+
"Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis"
|
1076 |
+
],
|
1077 |
+
"Osimertinib (mesylate)": [
|
1078 |
+
"EGFR, EGFR T790M, EGFR exon 19 deletion, EGFR exon 20 insertion",
|
1079 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT, NF-\u03baB",
|
1080 |
+
"Non-small cell lung cancer (NSCLC) with specific EGFR mutations, including T790M, exon 19 deletion, or exon 21 L858R"
|
1081 |
+
],
|
1082 |
+
"Levobupivacaine (hydrochloride)": [
|
1083 |
+
"Sodium channels, voltage-gated calcium channels",
|
1084 |
+
"Neurotransmission, pain signaling, inflammatory response",
|
1085 |
+
"Local anesthesia, regional anesthesia, surgical anesthesia, pain management"
|
1086 |
+
],
|
1087 |
+
"Imiquimod (maleate)": [
|
1088 |
+
"Toll-like receptor 7 and 8",
|
1089 |
+
"Immune response, cytokine production, cell proliferation, apoptosis",
|
1090 |
+
"Actinic keratosis, superficial basal cell carcinoma, external genital and perianal warts"
|
1091 |
+
],
|
1092 |
+
"Mozavaptan": [
|
1093 |
+
"Vasopressin V2 receptor, Vasopressin V1a receptor",
|
1094 |
+
"Renin-angiotensin-aldosterone system, Aquaporin-2 regulation, Osmoregulation",
|
1095 |
+
"Hyponatremia, Syndrome of inappropriate antidiuretic hormone secretion (SIADH)"
|
1096 |
+
],
|
1097 |
+
"Thymol": [
|
1098 |
+
"Cyclooxygenase enzymes, Acetylcholinesterase",
|
1099 |
+
"Inflammation, Oxidative stress, Neurotransmission",
|
1100 |
+
"Antimicrobial, Antifungal, Anthelmintic"
|
1101 |
+
],
|
1102 |
+
"Dorzolamide (hydrochloride)": [
|
1103 |
+
"Carbonic anhydrase II, Carbonic anhydrase IV",
|
1104 |
+
"Aqueous humor production, Intraocular pressure regulation, Ion transport",
|
1105 |
+
"Glaucoma, Ocular hypertension"
|
1106 |
+
],
|
1107 |
+
"Tranilast": [
|
1108 |
+
"Transforming growth factor beta (TGF-\u03b2)",
|
1109 |
+
"Fibrosis, inflammation, cell proliferation",
|
1110 |
+
"Hypertrophic scarring, keloids, allergic rhinitis, asthma"
|
1111 |
+
],
|
1112 |
+
"AZD2858": [
|
1113 |
+
"PI3K, mTOR, AKT",
|
1114 |
+
"Cell proliferation, Apoptosis, Glycolysis",
|
1115 |
+
"Breast cancer, Renal cell carcinoma, Non-small cell lung cancer"
|
1116 |
+
],
|
1117 |
+
"Almonertinib (mesylate)": [
|
1118 |
+
"MET, AXL, DDR1, DDR2",
|
1119 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
1120 |
+
"Non-small cell lung cancer"
|
1121 |
+
],
|
1122 |
+
"Docetaxel (Trihydrate)": [
|
1123 |
+
"Microtubules, tubulin",
|
1124 |
+
"Cell cycle regulation, apoptosis, angiogenesis",
|
1125 |
+
"Breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer"
|
1126 |
+
],
|
1127 |
+
"Tolcapone": [
|
1128 |
+
"Catechol-O-methyltransferase (COMT)",
|
1129 |
+
"Dopaminergic signaling, nigrostriatal pathway, catecholamine metabolism",
|
1130 |
+
"Parkinson's disease"
|
1131 |
+
],
|
1132 |
+
"NG25": [
|
1133 |
+
"TRKA, TRKB, TRKC",
|
1134 |
+
"PI3K/AKT, MAPK/ERK, NF-\u03baB",
|
1135 |
+
"Pain management, cancer"
|
1136 |
+
],
|
1137 |
+
"Adenosine": [
|
1138 |
+
"A1, A2A, A2B, A3 receptors",
|
1139 |
+
"Cardiovascular signaling, inflammatory response, neuronal modulation",
|
1140 |
+
"Supraventricular tachycardia, perioperative tachycardia and fibrillation, diagnostic imaging"
|
1141 |
+
],
|
1142 |
+
"Bergenin": [
|
1143 |
+
"Cyclooxygenase-2, Alpha-glucosidase, DNA topoisomerase II",
|
1144 |
+
"Inflammation, Carbohydrate digestion, Cell cycle regulation",
|
1145 |
+
"Type 2 diabetes, Hyperlipidemia, Hepatoprotection"
|
1146 |
+
],
|
1147 |
+
"Tubulin inhibitor 6": [
|
1148 |
+
"Tubulin",
|
1149 |
+
"Cell cycle arrest, apoptosis, angiogenesis inhibition",
|
1150 |
+
"Breast cancer, non-small cell lung cancer, ovarian cancer"
|
1151 |
+
],
|
1152 |
+
"Verapamil": [
|
1153 |
+
"L-type calcium channels",
|
1154 |
+
"Calcium signaling, cardiac conduction, vascular smooth muscle contraction",
|
1155 |
+
"Hypertension, angina pectoris, supraventricular tachycardia"
|
1156 |
+
],
|
1157 |
+
"Sonidegib": [
|
1158 |
+
"Smoothened",
|
1159 |
+
"Hedgehog signaling pathway, cell cycle regulation, apoptosis",
|
1160 |
+
"Adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy, metastatic basal cell carcinoma"
|
1161 |
+
],
|
1162 |
+
"Ropivacaine (hydrochloride monohydrate)": [
|
1163 |
+
"Sodium channels, voltage-gated calcium channels",
|
1164 |
+
"Inhibition of neuronal signaling, reduction of nociceptive transmission, modulation of sympathetic nervous system activity",
|
1165 |
+
"Local anesthesia, surgical anesthesia, pain management"
|
1166 |
+
],
|
1167 |
+
"Bentamapimod": [
|
1168 |
+
"p38 MAP kinase, JNK, MK2",
|
1169 |
+
"Apoptosis, cell proliferation, inflammatory response",
|
1170 |
+
"None"
|
1171 |
+
],
|
1172 |
+
"Entrectinib": [
|
1173 |
+
"NTRK1, NTRK2, NTRK3, ROS1, ALK, TRKA, TRKB, TRKC",
|
1174 |
+
"MAPK, PI3K/AKT, JAK/STAT",
|
1175 |
+
"Non-small cell lung cancer, solid tumors with NTRK fusion, thyroid cancer"
|
1176 |
+
],
|
1177 |
+
"LY-2584702 (tosylate salt)": [
|
1178 |
+
"mTOR, PI3K, AKT",
|
1179 |
+
"Cell growth, Cell proliferation, Apoptosis",
|
1180 |
+
"Advanced renal cell carcinoma, Advanced breast cancer"
|
1181 |
+
],
|
1182 |
+
"Isocorydine": [
|
1183 |
+
"Opioid receptors, dopamine receptors",
|
1184 |
+
"Pain signaling, reward processing, neurotransmitter release",
|
1185 |
+
"Pain management, cough suppression, diarrhea treatment"
|
1186 |
+
],
|
1187 |
+
"GSK1059615": [
|
1188 |
+
"Syk kinase",
|
1189 |
+
"PI3K/AKT, NF-\u03baB, B-cell receptor signaling",
|
1190 |
+
"Rheumatoid arthritis"
|
1191 |
+
],
|
1192 |
+
"Niclosamide (olamine)": [
|
1193 |
+
"STAT3, mTOR, SIRT1, NF-\u03baB",
|
1194 |
+
"Apoptosis, Autophagy, Cell cycle regulation, Inflammatory response",
|
1195 |
+
"Intestinal tapeworm infection, Hookworm disease"
|
1196 |
+
],
|
1197 |
+
"Anethole trithione": [
|
1198 |
+
"Nuclear receptors, GABA receptors, muscarinic receptors",
|
1199 |
+
"Inflammation, nociception, gastrointestinal motility",
|
1200 |
+
"Gallstones, biliary dyskinesia"
|
1201 |
+
],
|
1202 |
+
"Ligustrazine": [
|
1203 |
+
"CD36, COX-2, NF-\u03baB, PI3K/Akt",
|
1204 |
+
"Inflammation, angiogenesis, apoptosis",
|
1205 |
+
"Cerebrovascular disease, coronary heart disease, ischemic stroke"
|
1206 |
+
],
|
1207 |
+
"Amsacrine": [
|
1208 |
+
"Topoisomerase II",
|
1209 |
+
"DNA replication, cell cycle progression, apoptosis",
|
1210 |
+
"Acute leukemia"
|
1211 |
+
],
|
1212 |
+
"Tucidinostat": [
|
1213 |
+
"HDAC1, HDAC2, HDAC3, HDAC4",
|
1214 |
+
"Apoptosis, cell cycle arrest, angiogenesis inhibition",
|
1215 |
+
"Relapsed or refractory peripheral T-cell lymphoma, acute myeloid leukemia"
|
1216 |
+
],
|
1217 |
+
"L-Eflornithine (monohydrochloride)": [
|
1218 |
+
"Ornithine decarboxylase",
|
1219 |
+
"Polyamine synthesis, cell cycle regulation, apoptosis",
|
1220 |
+
"Hirsutism, African trypanosomiasis"
|
1221 |
+
],
|
1222 |
+
"Clofarabine": [
|
1223 |
+
"DNA polymerase, ribonucleotide reductase, adenylate deaminase",
|
1224 |
+
"Apoptosis, cell cycle arrest, DNA synthesis inhibition",
|
1225 |
+
"Acute lymphoblastic leukemia, acute myeloid leukemia"
|
1226 |
+
],
|
1227 |
+
"Simotinib": [
|
1228 |
+
"EGFR, HER2, HER4, VEGFR2, PDGFR\u03b2",
|
1229 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT, VEGF signaling",
|
1230 |
+
"Non-small cell lung cancer, breast cancer"
|
1231 |
+
],
|
1232 |
+
"HI-TOPK-032": [
|
1233 |
+
"TOPK, PLK1",
|
1234 |
+
"Cell cycle regulation, DNA damage response, apoptosis",
|
1235 |
+
"Acute myeloid leukemia, solid tumors"
|
1236 |
+
],
|
1237 |
+
"Olanzapine": [
|
1238 |
+
"Dopamine D2, serotonin 5-HT2A, muscarinic M1, histamine H1",
|
1239 |
+
"Dopaminergic, serotonergic, cholinergic, glutamatergic",
|
1240 |
+
"Schizophrenia, bipolar disorder, major depressive disorder"
|
1241 |
+
],
|
1242 |
+
"Flutamide": [
|
1243 |
+
"Androgen receptor",
|
1244 |
+
"Steroid hormone biosynthesis, cell cycle regulation, apoptosis",
|
1245 |
+
"Hormone-resistant prostate cancer, polycystic ovary syndrome, hirsutism, acne"
|
1246 |
+
],
|
1247 |
+
"Piroxicam": [
|
1248 |
+
"COX-1, COX-2",
|
1249 |
+
"Prostaglandin synthesis, Inflammatory response, Pain signaling",
|
1250 |
+
"Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Primary dysmenorrhea"
|
1251 |
+
],
|
1252 |
+
"Cytarabine": [
|
1253 |
+
"DNA polymerase, ribonucleotide reductase, DNA primase",
|
1254 |
+
"Nucleotide metabolism, DNA synthesis, cell cycle regulation",
|
1255 |
+
"Acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, meningeal leukemia"
|
1256 |
+
],
|
1257 |
+
"Bestatin (hydrochloride)": [
|
1258 |
+
"Aminopeptidase N, leucine aminopeptidase, arginine aminopeptidase",
|
1259 |
+
"Cell adhesion, immune response, angiogenesis",
|
1260 |
+
"Acute non-lymphocytic leukemia, malignant lymphoma, bladder cancer"
|
1261 |
+
],
|
1262 |
+
"Aprepitant": [
|
1263 |
+
"Neurokinin 1 (NK1) receptor",
|
1264 |
+
"Substance P signaling, nausea and vomiting pathways, central nervous system signaling",
|
1265 |
+
"Prevention of acute and delayed chemotherapy-induced nausea and vomiting, prevention of postoperative nausea and vomiting"
|
1266 |
+
],
|
1267 |
+
"(R)-Verapamil (hydrochloride)": [
|
1268 |
+
"L-type calcium channels, P-glycoprotein",
|
1269 |
+
"Calcium signaling, cardiac conduction, vascular smooth muscle contraction",
|
1270 |
+
"Hypertension, angina pectoris, supraventricular tachycardia, atrial fibrillation"
|
1271 |
+
],
|
1272 |
+
"Vemurafenib": [
|
1273 |
+
"BRAF V600E kinase",
|
1274 |
+
"MAPK/ERK signaling, cell proliferation, apoptosis",
|
1275 |
+
"Late-stage melanoma, Erdheim-Chester disease, hairy cell leukemia"
|
1276 |
+
],
|
1277 |
+
"c-Kit-IN-1": [
|
1278 |
+
"c-Kit, PDGFR, FLT3",
|
1279 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
1280 |
+
"Gastrointestinal stromal tumor, Acute myeloid leukemia, Mastocytosis"
|
1281 |
+
],
|
1282 |
+
"Lumateperone (tosylate)": [
|
1283 |
+
"5-HT2A receptors, dopamine D2 receptors, serotonin transporter",
|
1284 |
+
"Dopaminergic signaling, glutamatergic signaling, serotonergic signaling",
|
1285 |
+
"Schizophrenia, bipolar depression"
|
1286 |
+
],
|
1287 |
+
"Cepharanthine": [
|
1288 |
+
"P-glycoprotein, SARS-CoV-2 papain-like protease",
|
1289 |
+
"Apoptosis, autophagy, cell cycle regulation, NF-\u03baB signaling",
|
1290 |
+
"Biliary cirrhosis, hepatic disorders, snake bites, protozoal infections"
|
1291 |
+
],
|
1292 |
+
"Riluzole hydrochloride": [
|
1293 |
+
"Glutamate receptors, voltage-dependent sodium channels",
|
1294 |
+
"Excitatory neurotransmission, neuroinflammation, apoptosis",
|
1295 |
+
"Amyotrophic lateral sclerosis"
|
1296 |
+
],
|
1297 |
+
"Capmatinib": [
|
1298 |
+
"MET, AXL, FLT3, KIT, PDGFR\u03b1/\u03b2, TRKA/B/C, DDR2, DDR1",
|
1299 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT, PLC\u03b3/PKC",
|
1300 |
+
"Non-small cell lung cancer with MET exon 14 skipping mutation"
|
1301 |
+
],
|
1302 |
+
"Ribociclib": [
|
1303 |
+
"CDK4, CDK6",
|
1304 |
+
"PI3K/AKT, Rb, cell cycle progression",
|
1305 |
+
"HR-positive, HER2-negative advanced or metastatic breast cancer"
|
1306 |
+
],
|
1307 |
+
"Saquinavir": [
|
1308 |
+
"HIV-1 protease",
|
1309 |
+
"Cell signaling, apoptosis, cell cycle regulation, viral replication",
|
1310 |
+
"HIV-1 infection, AIDS"
|
1311 |
+
],
|
1312 |
+
"Gallic acid (hydrate)": [
|
1313 |
+
"Estrogen receptors, COX-2, NF-\u03baB, p53, STAT3",
|
1314 |
+
"Apoptosis, cell cycle regulation, inflammation, oxidative stress",
|
1315 |
+
"Wound healing, antimicrobial, antiviral, gastrointestinal disorders"
|
1316 |
+
],
|
1317 |
+
"Palmatine (chloride)": [
|
1318 |
+
"COX-1, COX-2, STAT3, NF-\u03baB, PI3K/Akt",
|
1319 |
+
"Inflammation, cell proliferation, apoptosis, angiogenesis",
|
1320 |
+
"Diarrhea, dysentery, bacterial infections, intestinal infections"
|
1321 |
+
],
|
1322 |
+
"Belzutifan": [
|
1323 |
+
"HIF2\u03b1",
|
1324 |
+
"Hypoxia-inducible factor signaling, cellular metabolism, angiogenesis",
|
1325 |
+
"Von Hippel-Lindau disease-associated renal cell carcinoma, other advanced renal cell carcinomas"
|
1326 |
+
],
|
1327 |
+
"Fingolimod (hydrochloride)": [
|
1328 |
+
"S1P receptors",
|
1329 |
+
"Immune cell circulation, lymphocyte recirculation, vascular integrity",
|
1330 |
+
"Relapsing forms of multiple sclerosis, secondary progressive multiple sclerosis"
|
1331 |
+
],
|
1332 |
+
"Bestatin": [
|
1333 |
+
"Aminopeptidase N, leukotriene A4 hydrolase, arginyl aminopeptidase",
|
1334 |
+
"Cell adhesion, immune response, inflammation",
|
1335 |
+
"Acute nonlymphocytic leukemia, aplastic anemia, myelodysplastic syndrome"
|
1336 |
+
],
|
1337 |
+
"Diphenhydramine": [
|
1338 |
+
"Histamine H1 receptor",
|
1339 |
+
"Sedation, anticholinergic, antiemetic pathways",
|
1340 |
+
"Insomnia, allergic reactions, motion sickness, itching, extrapyramidal symptoms"
|
1341 |
+
],
|
1342 |
+
"Pentoxifylline": [
|
1343 |
+
"Phosphodiesterase, TNF-\u03b1, interleukin-1, interleukin-6",
|
1344 |
+
"Inflammation, immune response, angiogenesis, apoptosis",
|
1345 |
+
"Intermittent claudication, peripheral artery disease, cerebrovascular disorders"
|
1346 |
+
],
|
1347 |
+
"Entecavir (monohydrate)": [
|
1348 |
+
"HBV DNA polymerase",
|
1349 |
+
"Nucleotide metabolism, viral replication, cellular immune response",
|
1350 |
+
"Chronic hepatitis B, compensation liver disease, HIV co-infection with HBV"
|
1351 |
+
],
|
1352 |
+
"Atazanavir (sulfate)": [
|
1353 |
+
"HIV-1 protease",
|
1354 |
+
"Proteolytic processing, viral maturation, cell signaling",
|
1355 |
+
"Treatment of HIV-1 infection, HIV-1 infection in pediatric patients, HIV-1 infection in combination with other antiretroviral agents"
|
1356 |
+
],
|
1357 |
+
"Belumosudil": [
|
1358 |
+
"ROCK1, ROCK2",
|
1359 |
+
"PI3K/Akt, MAPK/ERK, NF-\u03baB",
|
1360 |
+
"Chronic graft-versus-host disease"
|
1361 |
+
],
|
1362 |
+
"Auranofin": [
|
1363 |
+
"Thioredoxin reductase, mitochondrial thioredoxin reductase",
|
1364 |
+
"NF-\u03baB signaling, MAPK signaling, PI3K/AKT signaling",
|
1365 |
+
"Rheumatoid arthritis"
|
1366 |
+
],
|
1367 |
+
"Fluvoxamine (maleate)": [
|
1368 |
+
"Serotonin transporter",
|
1369 |
+
"Neurotransmitter signaling, synaptic plasticity, mood regulation",
|
1370 |
+
"Obsessive-compulsive disorder, social anxiety disorder, major depressive disorder"
|
1371 |
+
],
|
1372 |
+
"Malotilate": [
|
1373 |
+
"Cytochrome P450 2C9, UDP-glucuronosyltransferase",
|
1374 |
+
"Lipid metabolism, bile acid synthesis, inflammation",
|
1375 |
+
"Hepatic disorders, liver protection, cirrhosis"
|
1376 |
+
],
|
1377 |
+
"Selinexor": [
|
1378 |
+
"XPO1",
|
1379 |
+
"NF-\u03baB, p53, PI3K/AKT, STAT3",
|
1380 |
+
"Multiple Myeloma, Diffuse Large B-Cell Lymphoma"
|
1381 |
+
],
|
1382 |
+
"Rifaximin": [
|
1383 |
+
"Bacterial RNA polymerase",
|
1384 |
+
"Inflammatory cascade, gut motility pathways, intestinal barrier function",
|
1385 |
+
"Hepatic encephalopathy, irritable bowel syndrome with diarrhea, travelers' diarrhea"
|
1386 |
+
],
|
1387 |
+
"Bimiralisib": [
|
1388 |
+
"PI3K, mTOR, AKT",
|
1389 |
+
"Apoptosis, Cell cycle regulation, Angiogenesis",
|
1390 |
+
"Peripheral T-cell lymphoma, Relapsed or refractory follicular lymphoma"
|
1391 |
+
],
|
1392 |
+
"Rosiglitazone": [
|
1393 |
+
"PPAR\u03b3",
|
1394 |
+
"Insulin signaling, glucose metabolism, lipid metabolism",
|
1395 |
+
"Type 2 diabetes mellitus"
|
1396 |
+
],
|
1397 |
+
"Bortezomib": [
|
1398 |
+
"26S proteasome",
|
1399 |
+
"NF-\u03baB signaling, cell cycle regulation, apoptosis",
|
1400 |
+
"Multiple myeloma, mantle cell lymphoma"
|
1401 |
+
],
|
1402 |
+
"Medroxyprogesterone acetate": [
|
1403 |
+
"Progesterone receptor",
|
1404 |
+
"Endometrial growth regulation, Menstrual cycle modulation, Gonadotropin release inhibition",
|
1405 |
+
"Contraception, Endometriosis, Abnormal uterine bleeding, Renal or breast cancer"
|
1406 |
+
],
|
1407 |
+
"Allopurinol": [
|
1408 |
+
"Xanthine oxidase",
|
1409 |
+
"Purine metabolism, uric acid production, oxidative stress",
|
1410 |
+
"Gout, high levels of uric acid, tumor lysis syndrome, recurrent calcium oxalate kidney stones"
|
1411 |
+
],
|
1412 |
+
"Zileuton": [
|
1413 |
+
"5-lipoxygenase",
|
1414 |
+
"Leukotriene synthesis, inflammation, immune response",
|
1415 |
+
"Asthma"
|
1416 |
+
],
|
1417 |
+
"Glasdegib": [
|
1418 |
+
"Hedgehog signaling pathway components, Smoothened",
|
1419 |
+
"Cell proliferation and survival, apoptosis, stem cell signaling",
|
1420 |
+
"Acute myeloid leukemia, myelodysplastic syndrome"
|
1421 |
+
],
|
1422 |
+
"AZD-8055": [
|
1423 |
+
"mTOR",
|
1424 |
+
"PI3K/Akt, cell cycle regulation, apoptosis",
|
1425 |
+
"None"
|
1426 |
+
],
|
1427 |
+
"NVP-BHG712": [
|
1428 |
+
"c-Met, Axl, DDR2",
|
1429 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
1430 |
+
"None"
|
1431 |
+
],
|
1432 |
+
"Sinomenine": [
|
1433 |
+
"COX-2, NF-\u03baB, TLR4, STAT3",
|
1434 |
+
"Inflammation, immune response, apoptosis, cell proliferation",
|
1435 |
+
"Rheumatoid arthritis, lupus, psoriasis, osteoarthritis"
|
1436 |
+
],
|
1437 |
+
"Crizotinib (hydrochloride)": [
|
1438 |
+
"MET, ALK, ROS1, RON",
|
1439 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT, mTOR",
|
1440 |
+
"Non-small cell lung cancer, ALK-positive metastatic non-small cell lung cancer, ROS1-positive metastatic non-small cell lung cancer"
|
1441 |
+
],
|
1442 |
+
"Sulfisoxazole": [
|
1443 |
+
"Dihydropteroate synthetase",
|
1444 |
+
"Folate synthesis pathway, bacterial cell wall synthesis",
|
1445 |
+
"Urinary tract infections, malaria, toxoplasmosis, meningitis, pneumonia, bronchitis"
|
1446 |
+
],
|
1447 |
+
"Gemcitabine": [
|
1448 |
+
"DNA synthetase, ribonucleotide reductase, DNA polymerase",
|
1449 |
+
"Apoptosis, cell cycle arrest, nucleotide metabolism",
|
1450 |
+
"Breast cancer, ovarian cancer, pancreatic cancer, non-small cell lung cancer"
|
1451 |
+
],
|
1452 |
+
"Oxaprozin": [
|
1453 |
+
"COX-1, COX-2",
|
1454 |
+
"Prostaglandin synthesis, Inflammatory response, Pain perception",
|
1455 |
+
"Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis, Juvenile rheumatoid arthritis"
|
1456 |
+
],
|
1457 |
+
"Tucatinib": [
|
1458 |
+
"HER2",
|
1459 |
+
"PI3K/AKT, MAPK/ERK, cell cycle regulation",
|
1460 |
+
"Breast cancer"
|
1461 |
+
],
|
1462 |
+
"Tirabrutinib": [
|
1463 |
+
"Bruton's tyrosine kinase (BTK)",
|
1464 |
+
"B-cell receptor signaling, NF-\u03baB signaling, PI3K/AKT signaling",
|
1465 |
+
"Mantle cell lymphoma, Waldenstr\u00f6m's macroglobulinemia"
|
1466 |
+
],
|
1467 |
+
"Terfenadine": [
|
1468 |
+
"Histamine H1 receptors",
|
1469 |
+
"Inflammation mediation, mast cell stabilization, vascular permeability regulation",
|
1470 |
+
"Allergic rhinitis, urticaria"
|
1471 |
+
],
|
1472 |
+
"EX229": [
|
1473 |
+
"CDK4, CDK6",
|
1474 |
+
"Cell cycle progression, DNA replication, Retinoblastoma protein regulation",
|
1475 |
+
"Breast cancer, HR-positive advanced or metastatic breast cancer"
|
1476 |
+
],
|
1477 |
+
"Epirubicin (hydrochloride)": [
|
1478 |
+
"DNA",
|
1479 |
+
"Apoptosis, cell cycle arrest, DNA replication inhibition",
|
1480 |
+
"Breast cancer, ovarian cancer, lung cancer, gastric cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma"
|
1481 |
+
],
|
1482 |
+
"Capivasertib": [
|
1483 |
+
"AKT1, AKT2, AKT3",
|
1484 |
+
"PI3K/AKT, mTOR, NF-\u03baB",
|
1485 |
+
"Advanced or metastatic breast cancer, castration-resistant prostate cancer"
|
1486 |
+
],
|
1487 |
+
"ERK5-IN-2": [
|
1488 |
+
"ERK5",
|
1489 |
+
"Cell proliferation, cell survival, angiogenesis",
|
1490 |
+
"None"
|
1491 |
+
],
|
1492 |
+
"Pralsetinib": [
|
1493 |
+
"RET kinase",
|
1494 |
+
"MAPK, PI3K/AKT, JAK/STAT",
|
1495 |
+
"Non-small cell lung cancer, medullary thyroid cancer"
|
1496 |
+
],
|
1497 |
+
"Fedratinib (hydrochloride hydrate)": [
|
1498 |
+
"Janus kinase 2 (JAK2)",
|
1499 |
+
"JAK-STAT signaling, cell proliferation, apoptosis",
|
1500 |
+
"Intermediate-2 or high-risk primary or secondary myelofibrosis, myeloproliferative neoplasm-associated myelofibrosis"
|
1501 |
+
],
|
1502 |
+
"Fulvestrant": [
|
1503 |
+
"Estrogen receptor",
|
1504 |
+
"PI3K/AKT, cell cycle regulation, apoptosis",
|
1505 |
+
"Advanced breast cancer, metastatic breast cancer, hormone receptor-positive breast cancer"
|
1506 |
+
],
|
1507 |
+
"crizotinib": [
|
1508 |
+
"MET, ALK, ROS1",
|
1509 |
+
"PI3K/AKT, MAPK/ERK, JAK/STAT",
|
1510 |
+
"Non-small cell lung cancer, ROS1-positive non-small cell lung cancer"
|
1511 |
+
],
|
1512 |
+
"MK-3903": [
|
1513 |
+
"FGFR1, FGFR2, FGFR3",
|
1514 |
+
"MAPK signaling, PI3K/AKT signaling, JAK/STAT signaling",
|
1515 |
+
"Hormone receptor-positive metastatic breast cancer, perioperative treatment of non-small cell lung cancer"
|
1516 |
+
],
|
1517 |
+
"Futibatinib": [
|
1518 |
+
"FGFR1, FGFR2, FGFR3, FGFR4",
|
1519 |
+
"MAPK/ERK, PI3K/AKT, JAK/STAT",
|
1520 |
+
"Cholangiocarcinoma, other FGFR-related cancers"
|
1521 |
+
],
|
1522 |
+
"Lipoic acid": [
|
1523 |
+
"Pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, dihydrolipoamide succinyltransferase",
|
1524 |
+
"Insulin signaling pathway, NF-\u03baB pathway, PI3K/Akt pathway",
|
1525 |
+
"Diabetic neuropathy, peripheral neuropathy"
|
1526 |
+
],
|
1527 |
+
"L-Thyroxine (sodium salt pentahydrate)": [
|
1528 |
+
"Thyroid hormone receptor alpha, Thyroid hormone receptor beta",
|
1529 |
+
"Metabolic pathways, Cellular growth and differentiation pathways, Developmental pathways",
|
1530 |
+
"Hypothyroidism, Pituitary thyroid-stimulating hormone (TSH) suppression, Thyroid cancer treatment"
|
1531 |
+
],
|
1532 |
+
"BI-78D3": [
|
1533 |
+
"CD137, OX40",
|
1534 |
+
"NF-\u03baB signaling, PI3K/AKT signaling, MAPK/ERK signaling",
|
1535 |
+
"None"
|
1536 |
+
],
|
1537 |
+
"CP21R7": [
|
1538 |
+
"CD38, CD138",
|
1539 |
+
"NF-\u03baB, JAK/STAT, PI3K/AKT",
|
1540 |
+
"Multiple myeloma, Light-chain amyloidosis"
|
1541 |
+
],
|
1542 |
+
"4EGI-1": [
|
1543 |
+
"eIF4E, eIF4G",
|
1544 |
+
"PI3K/AKT, MAPK/ERK, mTOR",
|
1545 |
+
"None"
|
1546 |
+
],
|
1547 |
+
"Mitoxantrone (dihydrochloride)": [
|
1548 |
+
"Topoisomerase II, DNA",
|
1549 |
+
"Apoptosis, Cell cycle arrest, DNA damage response",
|
1550 |
+
"Multiple sclerosis, Acute myeloid leukemia, Prostate cancer"
|
1551 |
+
],
|
1552 |
+
"Baicalin": [
|
1553 |
+
"COX-2, NF-\u03baB, PI3K, Akt, MAPK",
|
1554 |
+
"Inflammation, apoptosis, cell cycle regulation, immune response",
|
1555 |
+
"Upper respiratory tract infections, fever, influenza, hepatitis"
|
1556 |
+
],
|
1557 |
+
"Indacaterol (maleate)": [
|
1558 |
+
"Beta-2 adrenergic receptors",
|
1559 |
+
"Cyclic adenosine monophosphate signaling, bronchodilation, smooth muscle relaxation",
|
1560 |
+
"Chronic obstructive pulmonary disease, bronchospasm"
|
1561 |
+
],
|
1562 |
+
"Belinostat": [
|
1563 |
+
"HDAC1, HDAC2, HDAC3, HDAC6",
|
1564 |
+
"Apoptosis, cell cycle arrest, angiogenesis inhibition",
|
1565 |
+
"Peripheral T-cell lymphoma"
|
1566 |
+
],
|
1567 |
+
"Lonafarnib": [
|
1568 |
+
"farnesyltransferase",
|
1569 |
+
"Ras signaling, cell cycle regulation, apoptosis",
|
1570 |
+
"Hepatocellular carcinoma, progeroid laminopathies"
|
1571 |
+
],
|
1572 |
+
"Berbamine": [
|
1573 |
+
"Bcl-2, Bcl-xL, Mcl-1, STAT3, NF-\u03baB",
|
1574 |
+
"Apoptosis, cell cycle regulation, inflammation",
|
1575 |
+
"Leukemia, lymphoma, solid tumors"
|
1576 |
+
],
|
1577 |
+
"Rucaparib (phosphate)": [
|
1578 |
+
"PARP1, PARP2",
|
1579 |
+
"DNA repair, cell cycle arrest, apoptosis",
|
1580 |
+
"Ovarian cancer, fallopian tube cancer, peritoneal cancer"
|
1581 |
+
],
|
1582 |
+
"Brimonidine": [
|
1583 |
+
"Alpha-2 adrenergic receptors",
|
1584 |
+
"Sympathetic nervous system regulation, aqueous humor dynamics, intraocular pressure reduction",
|
1585 |
+
"Glaucoma, ocular hypertension, facial erythema in rosacea"
|
1586 |
+
],
|
1587 |
+
"Voriconazole": [
|
1588 |
+
"14\u03b1-demethylase",
|
1589 |
+
"Ergosterol biosynthesis, cell membrane integrity",
|
1590 |
+
"Invasive aspergillosis, candidemia, esophageal candidiasis, oropharyngeal candidiasis, disseminated candidiasis, coccidioidomycosis"
|
1591 |
+
],
|
1592 |
+
"Azithromycin (hydrate)": [
|
1593 |
+
"50S ribosomal subunit",
|
1594 |
+
"Protein synthesis, cell growth and division, inflammation",
|
1595 |
+
"Bacterial infections, community-acquired pneumonia, pelvic inflammatory disease, strep throat, sinusitis"
|
1596 |
+
],
|
1597 |
+
"Sacubitril/Valsartan": [
|
1598 |
+
"Neprilysin, Angiotensin II receptor type 1",
|
1599 |
+
"Renin-angiotensin-aldosterone system, Sympathetic nervous system, Natriuretic peptide system",
|
1600 |
+
"Heart failure with reduced ejection fraction"
|
1601 |
+
],
|
1602 |
+
"Vandetanib": [
|
1603 |
+
"RET, EGFR, VEGFR, c-KIT",
|
1604 |
+
"MAPK, PI3K/AKT, NF-\u03baB, VEGF signaling",
|
1605 |
+
"Late-stage medullary thyroid cancer"
|
1606 |
+
],
|
1607 |
+
"Triamcinolone": [
|
1608 |
+
"Glucocorticoid receptor",
|
1609 |
+
"Inflammation, immune response, apoptosis, cell growth",
|
1610 |
+
"Allergic rhinitis, asthma, atopic dermatitis, psoriasis, rheumatoid arthritis"
|
1611 |
+
],
|
1612 |
+
"Pyridoxine (hydrochloride)": [
|
1613 |
+
"Pyridoxal phosphate, pyridoxal kinase, glycogen phosphorylase, pyridoxine phosphate oxidase",
|
1614 |
+
"Glycogenolysis, gluconeogenesis, neurotransmitter synthesis, one-carbon metabolism",
|
1615 |
+
"Dietary supplement for pyridoxine deficiency, pyridoxine-dependent epilepsy, homocystinuria, neuropathy"
|
1616 |
+
],
|
1617 |
+
"Fluvoxamine": [
|
1618 |
+
"Sigma-1 receptor, serotonin transporter",
|
1619 |
+
"Neurotransmission, synaptic plasticity, neuroinflammation",
|
1620 |
+
"Obsessive-compulsive disorder, social anxiety disorder, major depressive disorder"
|
1621 |
+
],
|
1622 |
+
"Methylprednisolone succinate": [
|
1623 |
+
"Glucocorticoid receptor",
|
1624 |
+
"Inflammation, immune response, apoptosis, cell growth",
|
1625 |
+
"Allergic reactions, asthma, rheumatoid arthritis, blood disorders, certain cancers, respiratory distress syndrome, shock"
|
1626 |
+
],
|
1627 |
+
"Alpelisib": [
|
1628 |
+
"Phosphatidylinositol 3-kinase (PI3K) p110\u03b1 subunit",
|
1629 |
+
"PI3K/AKT/mTOR, cell cycle regulation, apoptosis",
|
1630 |
+
"HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer"
|
1631 |
+
],
|
1632 |
+
"Dabrafenib": [
|
1633 |
+
"BRAF V600 kinase",
|
1634 |
+
"MAPK/ERK signaling, cell proliferation, apoptosis",
|
1635 |
+
"Metastatic melanoma, non-small cell lung cancer, thyroid cancer, anaplastic thyroid cancer"
|
1636 |
+
],
|
1637 |
+
"Volasertib": [
|
1638 |
+
"PLK1",
|
1639 |
+
"Cell cycle progression, apoptosis, spindle assembly",
|
1640 |
+
"Acute myeloid leukemia"
|
1641 |
+
],
|
1642 |
+
"Ferulic acid": [
|
1643 |
+
"Estrogen receptors, COX-2, NF-\u03baB, iNOS",
|
1644 |
+
"Inflammation, antioxidant, cell cycle regulation, apoptosis",
|
1645 |
+
"Cancer, cardiovascular disease, neurodegenerative disorders, diabetes"
|
1646 |
+
],
|
1647 |
+
"Chlorhexidine (diacetate)": [
|
1648 |
+
"Bacterial cell membrane",
|
1649 |
+
"Cell wall synthesis, membrane disruption, microbial biofilm formation",
|
1650 |
+
"Skin disinfection, surgical scrub, mucous membrane disinfection, perioperative skin preparation"
|
1651 |
+
],
|
1652 |
+
"Quinestrol": [
|
1653 |
+
"Estrogen receptors",
|
1654 |
+
"Cell growth and differentiation, hormone regulation, reproductive system modulation",
|
1655 |
+
"Treatment of menopausal symptoms, menstrual disorders, and hormone replacement therapy"
|
1656 |
+
],
|
1657 |
+
"Esmolol (hydrochloride)": [
|
1658 |
+
"Beta-1 adrenergic receptors",
|
1659 |
+
"Adrenergic signaling, heart rate regulation, blood pressure control",
|
1660 |
+
"Supraventricular tachycardia, perioperative tachycardia and hypertension, sinus tachycardia"
|
1661 |
+
],
|
1662 |
+
"Rimonabant": [
|
1663 |
+
"CB1 receptors",
|
1664 |
+
"Lipid metabolism, glucose homeostasis, appetite regulation",
|
1665 |
+
"Obesity, smoking cessation"
|
1666 |
+
],
|
1667 |
+
"Asciminib": [
|
1668 |
+
"ABL1, BCR-ABL1",
|
1669 |
+
"BCR-ABL signaling, cell proliferation, apoptosis",
|
1670 |
+
"Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia"
|
1671 |
+
],
|
1672 |
+
"Allantoin": [
|
1673 |
+
"Keratin, DNA, cell membranes",
|
1674 |
+
"Wound healing, cell proliferation, tissue repair",
|
1675 |
+
"Wound care, skin ulcers, dermatitis, oral mucositis"
|
1676 |
+
],
|
1677 |
+
"Pemigatinib": [
|
1678 |
+
"FGFR1, FGFR2, FGFR3",
|
1679 |
+
"MAPK/ERK, PI3K/AKT, JAK/STAT",
|
1680 |
+
"Cholangiocarcinoma, Myeloid/lymphoid neoplasms"
|
1681 |
+
],
|
1682 |
+
"Ixazomib citrate": [
|
1683 |
+
"Proteasome",
|
1684 |
+
"NF-\u03baB signaling, cell cycle regulation, apoptosis",
|
1685 |
+
"Multiple myeloma"
|
1686 |
+
],
|
1687 |
+
"TAK-733": [
|
1688 |
+
"MEK1, MEK2",
|
1689 |
+
"MAPK/ERK pathway, PI3K/AKT pathway, cell cycle regulation",
|
1690 |
+
"None"
|
1691 |
+
],
|
1692 |
+
"XRK3F2": [
|
1693 |
+
"PI3K, mTOR, AKT",
|
1694 |
+
"Apoptosis, cell cycle regulation, angiogenesis",
|
1695 |
+
"Breast cancer, non-small cell lung cancer, renal cell carcinoma"
|
1696 |
+
],
|
1697 |
+
"Hydroxyfasudil": [
|
1698 |
+
"Rho kinase, protein kinase C",
|
1699 |
+
"Rho kinase pathway, actin cytoskeleton signaling, smooth muscle contraction",
|
1700 |
+
"Cerebral vasospasm, acute ischemic stroke, angina pectoris"
|
1701 |
+
],
|
1702 |
+
"Acetazolamide": [
|
1703 |
+
"Carbonic anhydrase",
|
1704 |
+
"Bicarbonate reabsorption, aqueous humor production, cerebrospinal fluid production",
|
1705 |
+
"Glaucoma, epilepsy, edema, altitude sickness"
|
1706 |
+
],
|
1707 |
+
"18\u03b2-Glycyrrhetinic acid": [
|
1708 |
+
"11\u03b2-Hydroxysteroid dehydrogenase type 1, glucocorticoid receptors, Toll-like receptor 4",
|
1709 |
+
"NF-\u03baB signaling, PI3K/Akt pathway, MAPK/ERK pathway",
|
1710 |
+
"Gastric ulcers, oral mucositis, eczema, dermatitis"
|
1711 |
+
],
|
1712 |
+
"Ornidazole": [
|
1713 |
+
"DNA, proteins, and cell membranes",
|
1714 |
+
"Apoptosis, cell cycle arrest, and DNA damage response",
|
1715 |
+
"Trichomoniasis, amoebiasis, giardiasis, and anaerobic bacterial infections"
|
1716 |
+
],
|
1717 |
+
"Anastrozole": [
|
1718 |
+
"Aromatase",
|
1719 |
+
"Estrogen receptor signaling, cell cycle regulation, apoptosis",
|
1720 |
+
"Breast cancer in postmenopausal women, including first-line treatment and treatment after tamoxifen"
|
1721 |
+
],
|
1722 |
+
"Hesperidin": [
|
1723 |
+
"VEGFR, COX-2, NF-\u03baB, PI3K/Akt",
|
1724 |
+
"Apoptosis, angiogenesis, inflammation, cell cycle regulation",
|
1725 |
+
"Hypertension, hyperlipidemia, cardiovascular disease, osteoporosis"
|
1726 |
+
],
|
1727 |
+
"Neratinib": [
|
1728 |
+
"HER2, HER3, HER4, EGFR",
|
1729 |
+
"PI3K/AKT, MAPK/ERK, cell cycle regulation",
|
1730 |
+
"Extended adjuvant treatment of early-stage HER2-positive breast cancer, metastatic HER2-positive breast cancer"
|
1731 |
+
],
|
1732 |
+
"Benproperine (phosphate)": [
|
1733 |
+
"Muscarinic acetylcholine receptors",
|
1734 |
+
"Cholinergic neurotransmission, smooth muscle contraction",
|
1735 |
+
"Chronic bronchitis, bronchial asthma, respiratory tract infections"
|
1736 |
+
],
|
1737 |
+
"Darinaparsin": [
|
1738 |
+
"SIRT1, SIRT2, thioredoxin reductase, glutathione S-transferase",
|
1739 |
+
"Apoptosis, cell cycle regulation, mitochondrial function, oxidative stress response",
|
1740 |
+
"None, currently no approved indications"
|
1741 |
+
],
|
1742 |
+
"Aliskiren": [
|
1743 |
+
"Renin",
|
1744 |
+
"Renin-angiotensin-aldosterone system, blood pressure regulation, fluid balance",
|
1745 |
+
"Hypertension"
|
1746 |
+
],
|
1747 |
+
"Bosentan (hydrate)": [
|
1748 |
+
"Endothelin receptors (ETA, ETB)",
|
1749 |
+
"Pulmonary vascular remodeling, endothelin signaling, vascular smooth muscle contraction",
|
1750 |
+
"Pulmonary arterial hypertension, digital ulcers in systemic sclerosis"
|
1751 |
+
],
|
1752 |
+
"Abemaciclib": [
|
1753 |
+
"CDK4, CDK6",
|
1754 |
+
"Cell cycle progression, DNA replication, Rb signaling",
|
1755 |
+
"HR-positive, HER2-negative advanced or metastatic breast cancer, HR-positive breast cancer"
|
1756 |
+
],
|
1757 |
+
"Cabozantinib (S-malate)": [
|
1758 |
+
"MET, VEGFR2, RET, KIT, FLT3, AXL",
|
1759 |
+
"Angiogenesis, Met signaling, MAPK/ERK signaling, PI3K/AKT signaling",
|
1760 |
+
"Renal cell carcinoma, Hepatocellular carcinoma, Medullary thyroid cancer"
|
1761 |
+
],
|
1762 |
+
"Lactate (calcium)": [
|
1763 |
+
"Calcium channels, lactate receptors, GPR81",
|
1764 |
+
"Glycolysis, gluconeogenesis, cellular respiration",
|
1765 |
+
"Hyperkalemia, hypocalcemia, cardiac arrest"
|
1766 |
+
],
|
1767 |
+
"Pemetrexed": [
|
1768 |
+
"Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase",
|
1769 |
+
"DNA synthesis, folate metabolism, cell cycle regulation",
|
1770 |
+
"Non-small cell lung cancer, malignant pleural mesothelioma"
|
1771 |
+
],
|
1772 |
+
"Ranolazine": [
|
1773 |
+
"Sodium channels, potassium channels, late sodium current (INa)",
|
1774 |
+
"Cardiac myocyte function, sodium homeostasis, action potential duration",
|
1775 |
+
"Angina pectoris, chronic angina, coronary artery disease"
|
1776 |
+
],
|
1777 |
+
"Pentagastrin": [
|
1778 |
+
"Gastrin receptors",
|
1779 |
+
"Gastric acid secretion, gastrointestinal motility, pancreatic secretion",
|
1780 |
+
"Zollinger-Ellison syndrome, gastric acid hypersecretion"
|
1781 |
+
],
|
1782 |
+
"Penfluridol": [
|
1783 |
+
"Dopamine D2 and D3 receptors, serotonin 5-HT2A receptors",
|
1784 |
+
"Dopaminergic, serotonergic, and neurochemical signaling pathways",
|
1785 |
+
"Schizophrenia, anxiety, and other psychotic disorders"
|
1786 |
+
],
|
1787 |
+
"Encorafenib": [
|
1788 |
+
"BRAF V600E kinase",
|
1789 |
+
"MAPK/ERK signaling, PI3K/AKT signaling, cell cycle regulation",
|
1790 |
+
"BRAF V600E mutation-positive metastatic melanoma, BRAF V600E mutation-positive unresectable or metastatic colorectal cancer"
|
1791 |
+
],
|
1792 |
+
"Artesunate": [
|
1793 |
+
"PfATP6, SERCA",
|
1794 |
+
"Apoptosis, Autophagy, Cell cycle arrest, Endoplasmic reticulum stress",
|
1795 |
+
"Malaria, Severe malaria, Cerebral malaria"
|
1796 |
+
],
|
1797 |
+
"Larotrectinib sulfate": [
|
1798 |
+
"NTRK1, NTRK2, NTRK3",
|
1799 |
+
"MAPK, PI3K/AKT, cell cycle regulation",
|
1800 |
+
"Neurotrophic receptor tyrosine kinase fusion-positive solid tumors, infantile fibrosarcoma, congenital mesoblastic nephroma, secretory breast carcinoma"
|
1801 |
+
],
|
1802 |
+
"Dimethyl fumarate": [
|
1803 |
+
"Nrf2, NF-\u03baB, STAT1, STAT3",
|
1804 |
+
"Oxidative stress response, inflammation, immune response",
|
1805 |
+
"Relapsing-remitting multiple sclerosis, psoriasis, moderate to severe plaque psoriasis"
|
1806 |
+
],
|
1807 |
+
"Regorafenib": [
|
1808 |
+
"VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit, RET, RAF",
|
1809 |
+
"Angiogenesis, tumor growth and metastasis, cell proliferation and survival",
|
1810 |
+
"Colorectal cancer, gastrointestinal stromal tumor, hepatocellular carcinoma"
|
1811 |
+
],
|
1812 |
+
"Minodronic acid": [
|
1813 |
+
"Cathepsin K, RANKL, osteoclasts",
|
1814 |
+
"Bone resorption, osteoclast formation, calcium metabolism",
|
1815 |
+
"Osteoporosis, bone metastases, Paget's disease"
|
1816 |
+
],
|
1817 |
+
"Cloxacillin (sodium)": [
|
1818 |
+
"Penicillin-binding proteins",
|
1819 |
+
"Bacterial cell wall synthesis, peptidoglycan layer formation",
|
1820 |
+
"Skin and soft tissue infections, respiratory tract infections, osteomyelitis"
|
1821 |
+
],
|
1822 |
+
"Menadione": [
|
1823 |
+
"Vitamin K2, Vitamin K3",
|
1824 |
+
"Blood coagulation, bone metabolism",
|
1825 |
+
"Vitamin K deficiency, bleeding diathesis"
|
1826 |
+
],
|
1827 |
+
"Ralimetinib dimesylate": [
|
1828 |
+
"p38 MAPK",
|
1829 |
+
"Inflammation signaling, Cell proliferation, Apoptosis regulation",
|
1830 |
+
"Moderate to severe rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis"
|
1831 |
+
],
|
1832 |
+
"Ritonavir": [
|
1833 |
+
"CYP3A4, HIV-1 protease",
|
1834 |
+
"Cell signaling, lipid metabolism, proteolysis",
|
1835 |
+
"HIV-1 infection, AIDS"
|
1836 |
+
],
|
1837 |
+
"Fenofibrate": [
|
1838 |
+
"Peroxisome proliferator-activated receptor alpha (PPAR\u03b1)",
|
1839 |
+
"Lipid metabolism, glucose homeostasis, inflammation",
|
1840 |
+
"Hypertriglyceridemia, mixed dyslipidemia, primary hypercholesterolemia"
|
1841 |
+
],
|
1842 |
+
"Tirabrutinib (hydrochloride)": [
|
1843 |
+
"Bruton's tyrosine kinase (BTK)",
|
1844 |
+
"B-cell receptor signaling, NF-\u03baB signaling, PI3K/AKT signaling",
|
1845 |
+
"Mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstr\u00f6m's macroglobulinemia"
|
1846 |
+
],
|
1847 |
+
"Captopril": [
|
1848 |
+
"Angiotensin-converting enzyme (ACE)",
|
1849 |
+
"Renin-angiotensin-aldosterone system, blood pressure regulation, electrolyte balance",
|
1850 |
+
"Hypertension, heart failure, diabetic nephropathy, left ventricular dysfunction"
|
1851 |
+
],
|
1852 |
+
"Docetaxel": [
|
1853 |
+
"Microtubules, tubulin",
|
1854 |
+
"Cell cycle arrest, apoptosis, angiogenesis inhibition",
|
1855 |
+
"Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer"
|
1856 |
+
],
|
1857 |
+
"BAY1125976": [
|
1858 |
+
"BRAF, MEK1, MEK2",
|
1859 |
+
"MAPK/ERK signaling, cell cycle regulation, apoptosis",
|
1860 |
+
"Metastatic melanoma, colorectal cancer, anaplastic thyroid cancer"
|
1861 |
+
],
|
1862 |
+
"Celecoxib": [
|
1863 |
+
"COX-2",
|
1864 |
+
"Prostaglandin synthesis, Pain signaling, Inflammatory response",
|
1865 |
+
"Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis, Acute pain, Primary dysmenorrhea"
|
1866 |
+
],
|
1867 |
+
"Clobetasol propionate": [
|
1868 |
+
"Glucocorticoid receptor",
|
1869 |
+
"Inflammation, immune response, apoptosis",
|
1870 |
+
"Psoriasis, eczema, dermatitis"
|
1871 |
+
],
|
1872 |
+
"Dapagliflozin ((2S)-1,2-propanediol, hydrate)": [
|
1873 |
+
"Sodium-glucose cotransporter 2 (SGLT2)",
|
1874 |
+
"Glucose reabsorption, insulin sensitivity, glucagon secretion, blood pressure regulation",
|
1875 |
+
"Type 2 diabetes, heart failure, chronic kidney disease"
|
1876 |
+
],
|
1877 |
+
"Pitavastatin (Calcium)": [
|
1878 |
+
"HMG-CoA reductase",
|
1879 |
+
"Cholesterol biosynthesis, lipoprotein metabolism, inflammation",
|
1880 |
+
"Hyperlipidemia, mixed dyslipidemia, primary dysbetalipoproteinemia"
|
1881 |
+
],
|
1882 |
+
"Panobinostat": [
|
1883 |
+
"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, HDAC11",
|
1884 |
+
"Cell cycle regulation, Apoptosis, Autophagy, Angiogenesis, Inflammation",
|
1885 |
+
"Multiple myeloma"
|
1886 |
+
],
|
1887 |
+
"Orlistat": [
|
1888 |
+
"Lipases (gastric and pancreatic)",
|
1889 |
+
"Lipid absorption, fatty acid synthesis, glucose metabolism",
|
1890 |
+
"Obesity, weight loss, weight management"
|
1891 |
+
],
|
1892 |
+
"Hexylresorcinol": [
|
1893 |
+
"Protein kinase C, topoisomerase II, DNA",
|
1894 |
+
"Apoptosis, cell cycle regulation, DNA replication",
|
1895 |
+
"Antiseptic, anthelmintic, antiprotozoal"
|
1896 |
+
]
|
1897 |
+
}
|
data/drug_summary_embeddings.npy
ADDED
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
1 |
+
version https://git-lfs.github.com/spec/v1
|
2 |
+
oid sha256:1fb4a37d8a6ec7f0abc2e7b5266c08537909a7b5b7a5adcc430f91de87fe9efc
|
3 |
+
size 1164416
|
data/drug_summary_lowd.npy
ADDED
@@ -0,0 +1,3 @@
|
|
|
|
|
|
|
|
|
1 |
+
version https://git-lfs.github.com/spec/v1
|
2 |
+
oid sha256:083dbd1e81e5fb3003904715e056d2cda8595e74fcdfd464d480023522093e0e
|
3 |
+
size 75928
|
data/semantic_features_combined.csv
ADDED
The diff for this file is too large to render.
See raw diff
|
|